Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nano One Granted Taiwanese Patent for Battery Applications
VANCOUVER, British Columbia, March 17, 2016 (GLOBE NEWSWIRE) -- Nano One Materials Corp. (TSX-V:NNO) (Frankfurt:LBMB) (“Nano One or the Company”) is pleased to announce the issuance of Taiwanese Patent No. 201207152 related to batteries utilizing the proprietary lithium mixed metal oxides developed by Nano One. The method for making the proprietary oxides is discussed in previously issued U.S. Patent Nos. 9,136,534 and 9,159,999.
Patent agent and Director, Dr. Joseph Guy states that “Nano One has now been issued three patents in relatively short order with only minor revisions indicating an exclusive technological position and this battery patent gives the Company intellectual property protection in a commercially significant application of its proprietary technology. The Company has additional patent applications pending in the US and foreign jurisdictions and this patent is evidence of an expanding intellectual property portfolio.”
“This battery patent is significant in a few ways,” explains CEO Dan Blondal, “and marks another milestone in the growth and valuation of Nano One’s patent portfolio. The Taiwanese are global battery players and this issuance provides validation and positioning in the Asian market. This third patent also extends Nano One’s patent portfolio across the value chain to include processing, materials and now batteries.”
NANO ONE MATERIALS CORP.
Dan Blondal, CEO
For information with respect to Nano One or the contents of this news release, please contact John Lando (President) at (604) 669-2701 or visit the website at www.nanoone.ca.
About Dr. Joseph Guy
Dr. Joseph Guy is Nano One’s patent agent and serves on Nano One’s board of directors. He is a Patent Agent with Perkins Law Firm’s Intellectual Property group focusing on complex technologies including material science, electronic components, pharmaceuticals and medical products. He has more than 23 years of experience prosecuting patents and serving as expert witness on intellectual property matters. Dr. Guy was awarded a Ph.D. in Chemistry from the University of Wisconsin-Milwaukee in physical inorganic chemistry with a focus on organometallic complexes. After a post-doctoral fellowship at Naval Research Laboratories, Dr. Guy joined E.I. duPont de Nemours & Co. in Brevard, North Carolina where he conducted research in medical imaging technologies.
Dr. Guy later transitioned to intellectual property manager where his primary responsibility was management of the Intellectual Property portfolio and license negotiations for the Medical Products Division. The Medical Products Division was divested to Sterling Diagnostic Imaging, Inc. in 1996 and Dr. Guy was appointed corporate patent manager responsible for managing the intellectual property for a multinational corporation. Dr. Guy has authored numerous references in peer-reviewed journals and has written and prosecuted over 1000 U.S. and foreign patent applications, with more than 400 issued U.S. Patents and numerous foreign patents. His corporate research, management experience and intellectual property backgrounds merge to provide excellent experience in the development of an IP portfolio tailored to augment corporate strategies.
About Nano One
Nano One Materials Corp. is developing novel and scalable processing technology for the and low-cost production of high performance battery materials used in electric vehicles, energy storage and consumer electronics. The patented technology can be configured for a wide range of nanostructured materials and has the flexibility to shift with emerging and future battery market trends and a diverse range other growth opportunities. The novel three-stage process uses equipment common to industry and is being engineered for high volume production and rapid commercialization. Nano One’s mission is to establish its patented technology as a leading platform for the global production of a new generation of nanostructured composite materials. For more information, please visit nanoone.ca
Axxess Pharma AXXE Prepares for Strong Revenue Growth in 2nd Half of 2015 -- Fueled by Their Latest Line of Tapout Products and Up-Listing to the OTCQB Stock Exchange
Financial Audits to Be Completed and Submitted to FINRA Within 30 Days
TORONTO, ON--(Marketwired - Jun 29, 2015) - Axxess Pharma Inc. (OTC PINK: AXXE), a company that develops a variety of nutritional supplements and specialty pharmaceutical products through its subsidiary company AllStar Health Brands Inc., is pleased to announce management projects a strong finish to the second half of 2015.
Currently, 2015 has been a year of aggressive marketing and global approvals to sell their all-natural Tapout supplements. Axxess Pharma is also proud to be a licensee for Tapout, the official fitness and training partner of WWE (Worldwide Wrestling Entertainment). To view the joint venture between Authentic Brands Group, LLC and WWE for Tapout, please click on the link: http://corporate.wwe.com/news/2015/abg-and-wwe-launch-tapout-joint-venture.
Management has now continued their growth by expanding their product line with new chocolate and peanut butter protein bars, pre-work out protein powders and new organic proteins. This latest product expansion comes at a time when supermarkets are preparing to sell Axxess Pharma's all-natural Tapout products in chain stores nationwide. In preparation for management's expansion into supermarkets, they have now reported they are in the final stage of completing their financial audits for up-listing to the more liquid OTCQB. Axxess Pharma anticipates audits will be completed within the next 30 days. Once audits are complete, management anticipates a quick up-listing to the OTCQB. There are many benefits to up-listing to the OTCQB. Some of these benefits include improved ease of trading, opportunity for increased liquidity and recognition by Wall Street brokers and major Financial Institutions.
Below are additional accomplishments by Axxess Pharma within the last 60 days.
•May 26, 2015: Axxess Pharma Announces Amazon.com Re-Orders of Company's Products - Amazon.com, well-known as the World's largest on-line retailer, has frequently sold-out Axxess Pharma's Tapout product. This re-order was for the all-natural Tapout Pain Relief Line and Extreme Muscle supplements.
•May 12, 2015: Axxess Pharma's All-Natural Tapout Products Now Available in Large North American Fitness Chain - The pilot program was initiated on April 27, 2015 and is currently generating strong sales within the two fitness centers. Axxess Pharma anticipates sales will remain strong and lead to the North American roll-out into all of the chain's 300 plus fitness centers across North America.
•May 6, 2015: Research Firm Murphy Analytics Re-Initiates Coverage on Axxess Pharma, Inc. with "Positive Outlook" - Axxess Pharma Projects $2.5 Million in Year over Year Sales from May 2015 to May 2016
•April 29, 2015: Axxess Pharma Signs Agreement to Expand Full Tapout Line Into Over 60 High Profile Shopping Centers Across Canada by Early Summer - Agreement Secured With "Nutrition House," Canada's Leading Health Product Franchise
•April 22, 2015: Axxess Pharma Signs Major Manufacturing, Marketing and Distribution Agreement with Chinese Manufacturer - Management Projects Agreement to Generate Additional $525,000 USD in First Year Sales Starting in Third Quarter 2015.
Dr. Bagi, President of Axxess Pharma, stated: "We are thrilled to have consummated these very important recent events, and will continue to integrate the Tapout line of products into global platforms with our new partners. The TapouT product lines, which represent natural yet effective sports and fitness options, provide a perfect synergy for military bases around the world as well fitness centers, nutrition houses such as GNC, and supermarkets across North America." Dr. Bagi further stated, "2015 continues to be a strong year for our company. We anticipate further expansion of sales and marketing in 2016. We also look to complete our financial audits within 60 days and quickly move to the more liquid OTCQB stock exchange."
About Axxess Pharma Inc.:
Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain -- to optimal health management through improved nutritional supplements.
NEWS
Helius Medical Technologies (HSDT) (HSM:CNX) Achieves Full Enrollment in Canadian MS Feasibility Study
Newtown, PA / TheNewswire / May 20th, 2015 - Helius Medical Technologies ("Helius", "HMT", or the "Company") announced that it has achieved full enrollment for its Multiple Sclerosis pilot clinical trial at the Montreal Neurological Institute. The trial, "Examining the efficacy of non-invasive neuromodulation in reducing symptoms of Multiple Sclerosis", launched in February 2015, is a 14 subject, blinded feasibility study investigating Helius' Portable Neuromodulation Stimulator (PoNS?) and physiotherapy protocol on the rehabilitation of balance and gait symptoms in subjects with Multiple Sclerosis.
Subjects enrolled in the study receive treatment with the PoNS device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the DGI (Dynamic Gait Index) and improvement in balance as measured by the Sensory Organization Test (SOT). The study, including data analysis, is expected to conclude in Q4 2015.
"Achieving full enrollment of this study within our forecasted timeline is a significant milestone for Helius and our research into Multiple Sclerosis," said Helius' CEO, Philippe Deschamps. "This pilot protocol is primarily designed to be an external validation of a previously published, internally managed study of similar design*. In addition, the results of this study will help inform the design of a larger, efficacy focused, registrational MS protocol anticipated to begin by the end of the year."
"We are proud of the significant progress that has been made in the clinical development and validation of this protocol. We are pleased with the smooth execution of the trial and we are looking forward to the data analyses, which we hope will reflect the hard work of both the clinical team and the subjects." added Dr. Gabriel Leonard, Principal Investigator of the study
* "Non-invasive neuromodulation to improve gait in chronic multiple sclerosis: a randomized double blind controlled pilot trial": Journal of NeuroEngineering and Rehabilitation 2014, 11:79
About the PoNS(TM)
The Portable Neuromodulation Stimulator (PoNSTM) device is an investigational medical device being studied for the treatment of neurological symptoms caused by disease or trauma as part of a physical therapy program. The PoNSTM is currently being studied in the United States for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury (mTBI), and in Canada for the treatment of gait and balance disorder for subjects with Multiple Sclerosis (MS).
The PoNSTM device is believed to be the first non-invasive means for delivering neurostimulation through the tongue. Researchers believe that use of the tongue as a gateway to the brain may be one of the most natural, non-invasive and direct ways to stimulate the brain. The tongue is anatomically unique, being richly innervated by thousands of nerve fibers and interconnected to the brainstem by two major cranial nerves.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to use unique and non-invasive platform technologies that amplify the brain's ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS(TM) device. For more information, please visit www.heliusmedical.com.
About the Montreal Neurological Institute
The Montreal Neurological Institute and Hospital - ("The Neuro") is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world's top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre.
Daremiester very in dept
Helius Medical Technologies Announces Closing of Cad $2,208,110 Non-Brokered Private Placement
(via Thenewswire.ca)
NEWTOWN, PA / TheNewswire / April 30, 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company") is pleased to announce that it has closed a non-brokered private placement (the "Financing") raising gross proceeds of CAD $2,208,110 (approximately USD $1,825,937) by the issuance of 849,273 units (each a "Unit") at a price of CAD $2.60 per Unit (USD $2.15 per Unit). Each Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Warrant"). Each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of approximately CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.
The Company has agreed to pay a cash finder's fee of CAD 101,494 (USD $84,074) in connection with this Financing, as well as 27,396 finder's warrants (the "Finder's Warrants"). Each Finder's Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.
All securities issued in this Financing are subject to a statutory hold period expiring on September 1, 2015.
The Financing will provide further funding for the development of the PoNSTM technology and for general corporate purposes.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company focused on neurological wellness. The company's mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. For more information, please visit www.heliusmedical.com.
taking shape for sure. can be a game changer
I agree with you.
Here are a few videos check them out
Coming into play here
Helius Medical Technologies (CSE: HSM; OTCQB: HSDT) Inventors' Granted US Patent No. 14/341,141
"Non-Invasive Neuromodulation (NINM) For Rehabilitation of Brain Function"
NEWTOWN, PA / TheNewswire / April 14, 2015 - Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company") announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS(TM)) device and the associated therapeutic modality. U.S. Patent No. 14/341,141 "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function", issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.
Cranial Nerve - Non Invasive Neuromodulation (CN-NINM) therapy is believed to facilitate the brain's ability to rehabilitate and compensate for symptoms caused by disease or trauma. The PoNS(TM) device and the CN-NINM therapy is currently being studied in the United States for the treatment of chronic balance disorders caused by mild-moderate Traumatic Brain Injury ("TBI") and in Canada for chronic balance and gait disorders caused by Multiple Sclerosis.
"Our growing patent portfolio continues to protect our vision to revolutionize the treatment of brain injury symptoms. Protecting our unique technology and therapeutic modality is fundamental for our growth as a company and our ability to properly and aggressively reshape this space," said Philippe Deschamps, Chief Executive Officer of Helius.
This USPTO issuance is the third patent Helius has received related to the PoNS(TM) device and the associated therapeutic modality. The first PoNS(TM) patent, US Patent No. 8,849,407, was issued on September 30, 2014. The second PoNS(TM) patent, US Patent No. 8,909,345 was issued on December 9, 2014. The Company also filed more than two dozen patent applications to protect the valuable technical features and ornamental design elements of the PoNS(TM) device. Helius expects to file additional patent applications to protect its technology, designs and therapeutic methods as they evolve.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company focused on neurological wellness. The company's mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. For more information, please visit www.heliusmedical.com.
Highbank's (TSX: HBK) (FRANKFURT: V7O) Swamp Point North Aggregate Plant Is Now Commissioned
VANCOUVER, BC--(Marketwired - April 14, 2015) - Highbank Resources Ltd. (the "Company") (TSX VENTURE: HBK) (FRANKFURT: V7O) -
Victor Bryant, CEO/President comments,
"Another Major Milestone has been Reached. Our Director- Jim Place, P.Geo. was on site for the commissioning of the wash plant, cone crusher, jaw crusher and stacking conveyor systems. To view the first production video (click #1 below). Mr. Place took several samples of the first production, adhering to proper handling protocol procedures. The samples were delivered to a certified testing laboratory in Terrace, B.C. where standard construction aggregate tests will be conducted to ensure compliance with end user specifications. Mr. Place also delivered samples of the initial Swamp Point North ("SPN") quarry run to sand and gravel consumers in Prince Rupert. The quality of our aggregates was well received. A potential new client will be visiting the operation in the next two weeks to ensure the compatibility of our load-out facility with their marine transport systems."
"Currently the plant is being used to produce crushed gravel for onsite haulage road and stockpile site upgrades. Once these improvements are completed SPN will move into full plant production mode and begin preparing aggregate stockpiles for shipments."
"Within a year of receiving our mine operating permit, we have seen the SPN -Portland Canal Quarry Project obtain funding, procure and transport to the site all necessary equipment, establish a year round camp, logged and cleared the site and expanded a road haulage network, construct a $multi- million marine load-out system, build a water recirculation pond for the aggregate washing plant, and commissioned all equipment for a fully functioning oceanside sand and gravel operation."
"We would like to thank all the parties involved, from investors to construction personnel for their optimism and confidence throughout these difficult market times, and the construction period. Highbank intends to continue its positive and productive pace, as we become a major aggregate supplier on the northwest coast of British Columbia, Canada."
3rd Annual Canadian LNG Exports Multi-Stakeholder Collaboration Initiative 2015 - April 15 & 16, 2015
Highbank' s Directors and Consultants will be exhibiting and attending for the second year at the Canadian LNG Exports Conference taking place at the Pan Pacific Hotel. The Conference attendees will be examining collaborate solutions for accelerating final investment decisions for Canadian LNG Export Projects by identifying opportunities for partnerships between terminal proponents, upstream producers, pipeline proponents, local communities, First nations, Asian buyers and Government bodies.
#1 - SPN Production video http://ow.ly/LyWYm
#2 - http://ow.ly/Lz436 (classical) & http://ow.ly/Lz0w2 (LP)
On behalf of the Board of Directors of
HIGHBANK RESOURCES LTD.
"Victor N. Bryant"
Victor N. Bryant, CEO/President
IntelGenx (TSXV: IGX) (OTCQX: IGXT) Founder, President and CEO Dr. Horst Zerbe Interviewed on Fox Business Network's "After the Bell"
Saint Laurent, Quebec--(Newsfile Corp. - April 10, 2015) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company" or "IntelGenx") today announced its President and CEO Dr. Horst G. Zerbe, was a guest on FOX Business Network's After the Bell (weekdays 4-5PM/ET) on Thursday, April 9, 2015.
During the show, Zerbe discussed the company's growth opportunities for its immediate-release, oral film technology, VersaFilm™. As an example, this technology is effective for the treatment of migraines. A replay of the segment can be found at the following link: http://video.foxbusiness.com/v/4163821880001
Dr. Zerbe has more than 30 years' experience in Pharmaceutical R&D, technology management, business development and corporate management. Prior to founding IntelGenx, Dr. Zerbe served as the president of Smartrix Technologies Inc. in Montreal, and as Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe holds more than 40 patents in drug delivery related fields and has published numerous scientific papers in recognized journals.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.
CONTACT:
Paul A. Simmons
Chief Financial Officer
IntelGenx Technologies Corp.
T: +1 514-331-7440+1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
IntelGenx (TSXV: IGX) (OTCQX: IGXT) Grants Stock Options
Saint Laurent, Quebec--(Newsfile Corp. - April 2, 2015) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx", or the "Company") announced today that the Company's board of directors granted options to acquire a total of 300,000 common shares under the 2006 Stock Option Plan, as amended.
Of the total stock options granted, 50,000 were granted to each of the following non-employee directors; Bernard Boudreau, John Marinucci, Ian Troup and Bernd Melchers. The options have an exercise price of US$0.62 (CAD$0.78), vest immediately, and expire on April 2, 2020. In addition, 100,000 options to acquire common shares were granted to John Durham, the Vice President, Manufacturing Operations of IntelGenx Corp. The options have an exercise price of US$0.62 (CAD$0.78), vest over a period of two years at the rate of 25% every six months, and expire on April 2, 2020.
Mr. Durham joined IntelGenx Corp as Vice President, Manufacturing Operations at the beginning of 2015. Prior to his appointment, from April 2014, he was engaged at IntelGenx as a consultant assisting in the planning and design of IntelGenx' state-of-the-art, fully cGMP compliant, manufacturing facility.
Mr. Durham has held executive leadership positions with several multinational and domestic pharmaceutical manufacturing operations. He has an extensive background in pharmaceutical operations and quality management, together with a strong record of achievement in a regulated business environment. From September 2011 to November 2013 Mr. Durham was Chief Operating Officer with Pharmetics, a leading private label manufacturer in Montreal. From May 2009, to July 2011, he was Vice President, Technical Operations with Labopharm, a pharmaceutical company in Montreal. From September 2007, to April 2009, Mr. Durham was Vice President, Business Development with PharmEng, a Canadian contract manufacturing company. From May 2003, to July 2007, he was President of Draxis Pharma, a leading contract manufacturing company in Canada, and a division of Draxis Health, which was traded on the TSX. He was also Vice President and General Manager, from March 1997 until April 2003, with Banner Pharmacaps Canada, a contract manufacturer of soft gelatine capsules. In addition, Mr. Durham also held positions in operations management with Novartis from 1994 to 1997 and in quality and operations management with Johnson and Johnson from 1983 to 1994.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.
Contact:
IntelGenx Corp.
Ingrid Zerbe
Corporate Secretary
514-331-7440514-331-7440
ingrid@intelgenx.com
www.intelgenx.com
Levon Resources Ltd.(TSX: LVN) (FRANKFURT: LO9) (OTCQX: LVNVF) Announces Definitive Agreement to Acquire SciVac Ltd.
VANCOUVER, BC--(Marketwired - March 20, 2015) - Levon Resources Ltd. ("Levon") (TSX: LVN) (FRANKFURT: LO9) (OTCQX: LVNVF) and SciVac Ltd. ("SciVac") announced today that they have entered into an arrangement pursuant to which Levon will acquire 100% of the issued and outstanding ordinary shares of SciVac by way of a court-approved plan of arrangement (the "Arrangement").
"I am excited to announce this transaction with SciVac, as I believe it will generate tremendous value for Levon shareholders," stated Ron Tremblay, President and Chief Executive Officer of Levon. "In a difficult market for resource issuers, we have chosen to preserve capital while seeking to identify alternatives to create shareholder value. The acquisition of SciVac gives Levon ownership of Sci-B-Vac™, a commercial stage, potentially best in class hepatitis B vaccine which could address a significant market opportunity. Levon shareholders will also maintain an interest in Levon's existing business and assets by receiving shares of a newly formed company which will hold Levon's existing resource assets."
Pursuant to the Arrangement, Levon shareholders will receive one new common share of Levon (each a "New Levon Share") and 0.5 of a common share (each, a "Spinco Share") of 1027949 BC Ltd., a newly formed exploration company ("Spinco") in exchange for each common share of Levon (each a "Levon Share") held by them. Upon closing of the Arrangement, Levon shareholders will hold 100% of the issued and outstanding Spinco Shares and 31.6% of the issued and outstanding New Levon Shares, with the former holders of SciVac Shares holding the remaining 68.4% of the issued and outstanding New Levon Shares. In addition to acquiring all of the issued and outstanding shares of SciVac, Levon will retain CAD $27M in cash. All other assets and liabilities of Levon will be transferred to or will be assumed by Spinco. At the closing of the Arrangement, Levon expects that in addition to holding all of Levon's mineral properties, including Levon's flagship Cordero Project, SpinCo will have approximately $20.1M in working capital, including approximately $3M in cash, a $1.1M convertible debenture as well as 35,178,572 shares of Pershing Gold Corporation with current estimated value of $16M. SpinCo will also hold a $2M Mexican value added tax receivable that Levon expects will be recovered. The total of $22.1M represents approximately 48% of Levon's working capital as at December 31, 2014.
"SciVac is pleased to announce this transaction with Levon in furtherance of our goal of expanding market opportunities for SciVac products in development, including Sci-B-Vac, our third-generation hepatitis B vaccine," said Dr. Curtis Lockshin, Chief Executive Officer for SciVac. "Sci-B-Vac has already been approved in several countries, including Israel, where it has been provided to hundreds of thousands of newborn children. We intend to pursue marketing approvals for Sci-B-Vac in the United States and other territories worldwide, initially focused on at-risk populations such as End-Stage Renal Disease and HIV patients. In addition, we believe the transaction will permit SciVac to cultivate a pipeline of other therapeutics, utilizing novel treatment approaches in various disease areas with unmet needs."
SciVac is currently a privately owned company, of which approximately 45% of the shares are owned by OPKO Health, Inc. (NYSE: OPK). OPKO's CEO and Chairman, Dr. Phillip Frost, commented, "This transaction with Levon presented an opportunity to unlock meaningful value for OPKO shareholders via OPKO's ownership interest in SciVac. SciVac is a commercial-stage biotech leader in protein engineering whose flagship product, Sci-B-Vac, is a superior next generation hepatitis B vaccine. Sci-B-Vac has received approval for use in ten countries including Israel, where it captures half the market for neonatal hepatitis B vaccinations, and is offered to adults who do not respond to competing hepatitis B vaccines. It appears positioned to expand the billion dollar global hepatitis B vaccine market upon successful completion of the FDA approval process."
The board of directors of Levon has unanimously approved the transaction and all directors and officers of Levon, collectively holding approximately 10.08% of the number of Levon Shares and 76.94% of the number of options to purchase Levon Shares (the "Levon Options") anticipated to be entitled to vote at a special meeting to consider the Arrangement, have agreed to vote in favour of the Arrangement.
Arrangement Details
The Arrangement will be effected by way of a court-approved plan of arrangement and will require the approval of at least 2/3 of the votes cast by Levon's shareholders and optionholders at a special meeting expected to take place in April 2015 (the "Meeting"). The transaction is also subject to applicable regulatory approvals, including approval of the TSX, and the satisfaction of certain closing conditions customary in transactions of this nature.
The Arrangement will result, through a series of transactions, in:
•Levon shareholders receiving one New Levon Share and 0.5 of a Spinco Share for each Levon share currently held by them;
•holders of SciVac Shares receiving that number of New Levon Shares representing 68.4% of the issued and outstanding New Levon Shares in exchange for the acquisition by Levon of all of the issued and outstanding SciVac Shares;
•the change of Levon's name to "SciVac Inc."; and
•the change of Spinco's name to "Levon Resources Ltd."
Holders of outstanding Levon stock options may exercise their options until the effective time of the Arrangement, at which time they will be cancelled.
On completion of the Arrangement, Spinco will own and operate the existing business of Levon and Levon will own and operate the existing business of SciVac. Levon shareholders who receive New Levon Shares and Spinco Shares under the Arrangement will hold 100% of the issued and outstanding Spinco Shares and 31.6% of the issued and outstanding New Levon Shares, with the former holders of SciVac Shares holding the remaining 68.4% of the issued and outstanding New Levon Shares.
After taking into consideration, among other things, the terms of the Arrangement, the unanimous recommendation of a special committee of Levon directors established to review the Arrangement and discussions with its legal and financial advisors, Levon's board of directors has unanimously concluded that the Arrangement is in the best interests of Levon and has approved the Arrangement. Levon's board of directors intends to recommend in the management information circular to be mailed in connection with the Meeting that Levon's shareholders and optionholders vote in favour of the Arrangement.
Subject to SciVac's right to match, Levon's board of directors may terminate the arrangement agreement in favour of an unsolicited superior proposal upon payment of a US$1 million break fee to SciVac.
Advisors
Levon's legal counsel is Stikeman Elliott LLP and Dorsey & Whitney LLP. Cassel Salpeter & Co., LLC is Levon's financial advisor.
About Levon Resources Ltd.
Levon is a gold and precious metals exploration Company, exploring the company's 100% owned flagship Cordero bulk tonnage silver, gold, zinc, and lead project near Hidalgo Del Parral, Chihuahua, Mexico.
About SciVac Ltd.
SciVac Ltd., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. SciVac's flagship product Sci-B-Vac is a recombinant 3rd generation hepatitis B vaccine. SciVac also offers contract development and manufacturing services to the life sciences and biotechnology markets.
ON BEHALF OF THE BOARD
Ron Tremblay
President and Chief Executive Officer
IntelGenx (TSXV: IGX) (OTCQX: IGXT) Reports 2014 Annual Results and Provides Corporate Development Update
Saint Laurent, Quebec--(Newsfile Corp. - March 31, 2015) - IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company" or "IntelGenx") today announced financial results for its fiscal year ended December 31, 2014 and provided an update on operational developments. All amounts are in U.S. Dollars, unless otherwise stated.
"IntelGenx closed fiscal 2014 with a very healthy bank balance, continuing strong sales growth of Forfivo XL®, and excellent R&D progress on our most promising VersaFilm™ projects", said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We also made significant progress towards establishing a manufacturing facility for our growing portfolio of VersaFilm™ projects. We finalized negotiations for a new lease agreement for 17,000ft² facilities, and we negotiated a construction agreement for the build-out of these new premises. In addition, we executed on a credit facility of up to CAD$3.5 million with BMO Bank of Montreal, and we ordered packaging equipment to complete our VersaFilm™ manufacturing line. We are looking forward to moving into our new premises in the third quarter of 2015 and to taking the next steps to position IntelGenx as the film development partner of choice, offering our pharmaceutical partners complete support from concept, through research and development, regulatory affairs, and commercial supply of our VersaFilm™ products. We have, with all of these undertakings, many challenges ahead. However, Management believes that we have both the financial and the human resource capacity to successfully execute on all of these activities."
Financial Results:
Cash on hand at December 31, 2014 was $4.4 million compared with cash of $5.0 million as at December 31, 2013. The decrease of $0.6 million in cash relates to the net effect of cash used in operating activities of $1.4 million (2013: $1.2 million), cash used in investing activities of $0.4 million (2013: $0.3 million), and an unrealized foreign exchange loss of $0.4 million (2013: $0.1 million), partly offset by cash provided by financing activities of $1.6 million (2013: $4.5 million). The net cash provided by financing activities in 2014 is attributable to proceeds received from the exercise of warrants, whereas the cash provided in 2013 consists of approximately $3.0 million from a registered public offering that we completed in December 2013, together with approximately $1.5 million in proceeds received from the exercise of warrants and stock options.
Accounts receivable totaled $0.7 million as at December 31, 2014 compared with $0.1 million at December 31, 2013. The accounts receivable balance at December 31, 2014 included an amount of $0.6 million that was invoiced to our commercialization partner for Forfivo XL®, Edgemont Pharmaceuticals LLP ("Edgemont"), in the fourth quarter of 2014. Payment against the invoice was received in February 2015.
Revenue for the year ended December 31, 2014 increased by 75% to $1.7 million, up from $0.9 million in the previous year. Revenue recorded in the year ended December 31, 2014 includes $1.1 million (2013 - $0.5 million) related to Forfivo XL®, our first FDA approved product launched in October 2012 under a licensing partnership with Edgemont. Revenue for the year ended December 31, 2014 also includes $0.6 million (2013: $0.5 million) in payments received for successfully achieving R&D development milestones for certain R&D development projects currently under development.
Total costs and expenses increased from $2.6 million in fiscal 2013 to $3.4 million in 2014, primarily as a result of an increase of $0.5 million in R&D expenses incurred in the development of our second Par project, which is progressing according to plan, expenses for the completion of a pilot biostudy with our proprietary VersaFilm™ tadalafil product for erectile dysfunction, and successful completion of a pilot clinical study for our VersaFilm™ product, indicated for the treatment of schizophrenia. In addition, selling, general and administration costs increased by $0.3 million due to an increase in directors' fees, legal expenses related to our Paragraph IV litigation with Wockhardt that was settled in November 2014, and fees for investor relations services.
The net loss increased from $1.6 million in fiscal 2013 to a loss of $1.7 million in 2014, and the loss per share was $0.03 (2013: $0.03).
Corporate Development Update
Product-related
Anti-depressant tablet, Forfivo XL®
Forfivo XL®, our first FDA approved product, was launched in October 2012 and is being marketed in the United States under the terms of a license agreement between us and Edgemont Pharmaceuticals. Forfivo XL® is indicated for the treatment of Major Depressive Disorder ("MDD") and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL® is bupropion, the same active ingredient used in the well-known antidepressant product Wellbutrin XL®. Prior to the launch of Forfivo XL®, most patients in the US requiring a 450mg dose of bupropion had been taking multiple tablets to achieve their 450mg dose requirement.
In August 2013 we announced receipt of a Paragraph IV Certification Letter from Wockhardt Bio AG, advising of the submission of an ANDA to the FDA requesting authorization to manufacture and market generic versions of Forfivo XL® 450 mg capsules in the United States. In November 2014 we announced that the Paragraph IV litigation with Wockhardt had been settled and that, under the terms of the settlement, Wockhardt has been granted the rights, with effect from January 15, 2018, to be the exclusive marketer and distributor of an authorized generic of Forfivo XL® in the U.S.
In December 2014 we announced that Edgemont had exercised its right to extend the license for the exclusive marketing of Forfivo XL® 450 mg tablets. In exchange, we received milestone payments of $0.65 million in December 2014 and $0.6 million in February 2015. All other financial obligations contained in the license agreement entered into by Edgemont and IntelGenx in February 2012, specifically launch-related and sales milestones, together with the contractual royalty rates on net sales of the product, remain in effect.
The commercialization of Forfivo XL® triggered launch-related milestone payments to us of up to $4.0 million, of which $1 million was received following commercial launch in October 2012. Based on current trends, Management expects that the remaining $3 million will be earned in fiscal 2015.
We recorded total revenue for Forfivo XL® in 2014 of approximately $1.1 million, compared with $0.5 million in 2013.
The level of sales achieved for Forfivo XL® in 2014 improved significantly when compared to the previous year. According to Symphony Health Solutions, a recognized market research firm, gross sales of Forfivo XL® totaled $8.9 million in the year ending December 31st, 2014 representing an increase of 230% compared with sales of $2.7 million in the preceding year. The number of Forfivo XL® prescriptions filled increased by 123% from approximately 16,761 in 2013 to 30,378 in 2014. The average month-on-month growth rate of Forfivo XL® throughout 2014 exceeded 9%. Management anticipates this trend to continue throughout 2015 and expects significantly higher revenue from the sales of Forfivo XL® in 2015.
Anti-migraine VersaFilm™
In March 2013 we submitted a 505(b)(2) NDA to the FDA for our novel oral thin-film formulation of Rizatriptan, the active drug in Maxalt-MLT® orally disintegrating tablets. Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. The thin-film formulation of Rizatriptan was developed in accordance with the co-development and commercialization agreement with RedHill using our proprietary immediate release VersaFilm™ oral drug delivery technology.
In June 2013 the FDA assigned a PDUFA action date of February 3, 2014 for the review of the NDA for marketing approval and in February 2014 we received a Complete Response Letter ("CRL") from the FDA informing us that certain questions and deficiencies remain that preclude the approval of the application in its present form.
In March 2014 we submitted our response to the FDA's CRL and in April, 2014 the FDA requested additional Chemistry, Manufacturing and Controls data. We also reported that the supplier of the Active Pharmaceutical Ingredient ("API") of the product has been issued with an "Import Alert" by the FDA. The Import Alert bans the import into the USA of all raw materials from the supplier's manufacturing facility, which therefore prohibits the import of any products using these raw materials, and effectively prevents our VersaFilm™ product from being approved by the FDA at this time. We continue to work together with RedHill, our development partner, on a variety of options to ensure continued supply of the raw material regardless of the result of these compliance issues and have already identified and audited an alternative API supplier. However, changing suppliers is financially expensive and is a time-consuming process. As a result, we believe that FDA approval of this product for the US market will be delayed until 2016.
In October 2014 we announced the submission of a Marketing Authorization Application ("MAA") to the German Federal Institute for Drugs and Medical Devices ("BfArM") seeking European marketing approval of our oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT®. The brand name RIZAPORT® was also conditionally approved by the FDA as part of the NDA review process in the U.S. The MAA was submitted under the European Mutual Recognition Procedure with Germany as the reference member state. The submission is supported by several studies, including a comparative bioavailability study which successfully established the bioequivalence between RIZAPORT® and the European reference drug. BfArM validated the MAA and initiated the formal review process of the application on November 25, 2014. BfArM's potential feedback regarding the MAA is expected during the second half of 2015.
It should be noted that BfArM is satisfied with the compliance status of the API and that therefore the Import Alert issued by the FDA has no effect upon the MAA submission in Europe.
Two new (undisclosed) projects
In January 2014 we announced the signing of another development and commercialization agreement with Par Pharmaceutical, Inc. for two new products.
Under the terms of the agreement, Par has obtained certain exclusive rights to market and sell our products in the USA. In exchange we will receive upfront and milestone payments, together with a share of the profits upon commercialization. In accordance with confidentiality clauses contained in the agreement, the specifics of the product descriptions, platform technologies and financial terms remain confidential.
Erectile Dysfunction VersaFilm™
In February 2014 we announced the completion of a pilot biostudy with our proprietary VersaFilm™ tadalafil product for erectile dysfunction that indicated bioequivalence with the brand product, Cialis® tablets. The company plans to submit a 505(b)(2) NDA in 2016 and have the product ready for commercialization upon expiry of the substance patent in 2017..
Schizophrenia VersaFilm™
In April 2014 we announced financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition to advisory services and technological expertise, the funding provided by NRC-IRAP will support further development of a product for the treatment of central nervous system (CNS) diseases and disorders, based upon our proprietary, oral thin film, VersaFilm™, technology.
In November 2014 we announced the successful completion of a pilot clinical study for our INT0036 VersaFilm™ product, which is intended for the treatment of schizophrenia-related disorders. INT0036 showed a significantly improved pharmacokinetic profile against the reference product. Therapeutically relevant plasma concentrations are reached significantly faster with our VersaFilm™ product compared to conventional tablets and confirm the suitability of the film product for the intended indication.
According to a Datamonitor Healthcare schizophrenia forecast published July 13, 2012, sales of schizophrenia drugs across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) were estimated at $5.2 billion in 2012 and by 2021, the market is forecast to grow to $6.9 billion at a compound annual growth rate ("CAGR") of 3.3%. The introduction of additional atypical antipsychotic depot injections, price increases in the US, and the use of pipeline drugs targeted against negative and cognitive symptoms alongside current antipsychotic treatments, are some of the catalysts for this growth. US sales were approximately $3.7 billion in 2012 and are forecast to grow at a CAGR of 4.7% until 2021.
In order to maintain our competitive advantage, we are unable to disclose further details related to this project at this time.
Proprietary Technology
In February 2014 we announced receipt of a Notice of Allowance ("NOA") from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. We also announced that a second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL®, our first FDA-approved product currently commercialized in the U.S.
In April 2014 we announced receipt of a third NOA from the USPTO for U.S. Patent Application Serial No. 12/836,810 entitled "Oral mucoadhesive dosage form" which covers our proprietary AdVersa™ mucoadhesive drug delivery technology.
These three NOA's conclude the examination of each U.S. patent application and resulted in the issuance of three U.S. patents that significantly strengthen our patent portfolio and provide further protection for our proprietary technologies.
Corporate
Leadership succession
In July 2014 we announced the resignation of Dr. Rajiv Khosla as President and Chief Executive Officer ("CEO"), and as a member of the Board, effective immediately.
Concurrently, our Board of Directors appointed Dr. Horst G. Zerbe, our Chairman of the Board, founder, and former President and CEO, to the positions of President and CEO.
New Facility
Subsequent to the end of the year, in March 2015 we finalized negotiations on various agreements in support of our plans to construct and relocate our current operations into a state-of-the-art facility that will allow the Company to establish manufacturing capabilities for its growing platform of VersaFilm™ products. The new facility will also increase the Company's pharmaceutical R&D and formulation capabilities.
The property is located at 6420 Abrams, St-Laurent, Quebec, and comprises approximately 17,000ft². Renovation of the new facility is expected to commence in the coming weeks and is anticipated to be completed within 6 months, enabling the Company to occupy the premises sometime in Q3, 2015.
We finalized negotiations for an agreement to lease approximately 17,000 square feet in a property located at 6420 Abrams, St-Laurent, Quebec (the "Lease"), which we expect to execute in the coming weeks. The Lease has a 10 year and 6 month term commencing on September 1, 2015 and IntelGenx retained two options to extend the Lease, with each option being for an additional five years. Under the terms of the Lease IntelGenx will be required to pay base rent of approximately CAD$110 thousand (approximately $95 thousand) per year, which will increase at a rate of CAD$0.25 ($0.22) per square foot every two years. The Company plans to use the newly leased space to manufacture its oral film VersaFilm™ products, to enlarge research and development capabilities, and for administration purposes.
We also finalized negotiations for an agreement for the construction of manufacturing facilities, laboratories, and offices within the property located at 6420 Abrams, St-Laurent, Quebec, at an aggregate cost of CAD$2.9 million (approximately $2.5 million), which we expect to execute in the coming weeks. The construction agreement will be awarded to BTL Construction Inc. ("BTL") in Quebec following a tender process that was completed in December 2014. BTL specializes in the renovation of existing buildings for pharmaceutical use and has completed projects for various major pharmaceutical companies. IntelGenx plans to fund this project from cash on hand. Construction is anticipated to be completed in Q3, 2015.
In March 2015 IntelGenx received CAD$500 thousand (approximately $430 thousand) in cash as part of a credit facility of up to CAD$3.5 million (approximately $3.0 million) negotiated with BMO Bank of Montreal ("BMO"). The credit facility is supported by a 50% guarantee under the Export Guarantee Program from Export Development Canada, Canada's export credit agency. Management expects disbursement of the remaining CAD$3.0 million ($2.6 million) to follow after BMO has reviewed (in August 2015) the Company's operating results for the first 6 months of 2015. The credit facility may be drawn down in multiple disbursements over 12 months and, after a 6 month moratorium on the capital, has a repayment term of up to 60 months. The financial covenants of the credit facility require the Company to maintain a Minimum Debt Service Coverage ratio of 1.25:1, and a Maximum Total Debt to Tangible Net Worth ratio of 2.5:1. Based upon Management's business forecasts and projections, Management believes that we will be able to fully comply with these financial covenants. As part of securing the credit facility, IntelGenx will maintain its operating bank account with BMO and will conduct all future banking transactions related to its business operations through BMO. IntelGenx intends to use the funds for the purchase and installation of new equipment for its new, state-of the-art, manufacturing facility.
In March 2015 IntelGenx placed an order for 2 packaging machines to be manufactured by Harro Höfliger Verpackungsmaschinen GmbH ("Harro Höfliger") and installed in its new, state-of the-art, manufacturing facility. Harro Hofliger is widely recognized as a high end supplier of production and packaging equipment, primarily to the pharmaceutical and medical device industries, and is noted for providing innovative, custom equipment to meet the needs of customers. IntelGenx' purchase order consists of one commercial grade packaging machine for the commercial packaging of its VersaFilm™ products, and one smaller machine for its R&D laboratories to be used for clinical trials, submission batches and manufacturing scale up. The purchase order, in the aggregate amount of approximately €1.5 million (approximately $1.6 million), requires immediate payment of a 20% deposit with a further 70% to be paid upon delivery of each machine and the balance of 10% to be paid upon satisfactory completion of a Site Acceptance Test of each machine. The laboratory packaging machine is expected to be delivered in Q3, 2015 and the commercial packaging machine is expected to be delivered in Q4, 2015. We intend to finance the acquisition of these 2 machines with the credit facility negotiated with BMO, as discussed above.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
IntelGenx (TSXV: IGX) (OTCQX: IGXT) to Report 2014 Annual Results and Provide Corporate Development Update on March 31, 2015
Saint Laurent, Quebec--(Newsfile Corp. - March 23, 2015) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx", or the "Company") a leading drug delivery company focused on the development of novel rapidly disintegrating delivery systems as well as oral controlled-release products, today announced that it will release its 2014 annual results for the period and full year ended December 31, 2014, on March 31, 2015 at the open of the financial markets.
An accompanying conference call will be hosted by Dr. Horst Zerbe, President and Chief Executive Officer, and Paul Simmons, Chief Financial Officer, to discuss the results and provide a business update. The call will be held at 10:00 a.m. ET, on April 1, 2015. Please refer to the information below for conference call dial-in information and webcast registration.
Conference dial-in: 201-689-7817201-689-7817
International dial-in: 877-269-7756877-269-7756 FREE
Conference Call Name: IntelGenx Management Update Call
Webcast Registration: CLICK HERE (http://w.on24.com/r.htm?e=971685&s=1&k=9AC0B49C5995F1EF50418D4FD765A8F5)
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
News!
GroGenesis (GROG) to Present to Central American Agriculture Industry
Company Sponsors Invitation-Only Event in Guatemala City March 19th
SPRINGVILLE, TN--(Marketwired - Mar 12, 2015) - GroGenesis, Inc., (OTCBB: GROG) ("GroGenesis" or the "Company"), rights holders, developers and manufacturers of innovative plant health enhancement products, is pleased to advise it will be presenting to an invitation-only group of qualified Central American agricultural industry leaders, stakeholders and government representatives on March 19, 2015 in Guatemala City, Guatemala.
The event aims to introduce the GroGenesis flagship products, AgraBlast and AgraBurst and to inform industry professionals from across Guatemala as well as from Mexico, El Salvador, Costa Rica, Panama and Nicaragua on the impact and benefits these products can offer to regional high value agricultural operations.
The presentation is scheduled to take place on Thursday, March 19, 2015 between 8:30am - 1:30pm at the Hotel Barceló Guatemala City, 7ª Avenida, 15-45. Zona 9, 01009 Guatemala City (http://bit.ly/1BthUPq).
The event will be moderated by GroGenesis management along with local representatives, and will feature a presentation by the Company's Senior Scientific Consultant, Dr. Helen Keenan who will explain the benefits of how AgraBlast and AgraBurst working together can boost yield and profitability in all types of agriculture.
Immediately upon the conclusion of the presentation, Dr. Keenan and representatives of the Company will be available for a question and answer period followed by opportunities for one-on-one meetings. Arrangements for private meetings can be made in advance by contacting Mr. Peter Zimeri at 502-5709-2850 or peterzimeri@gmail.com.
Mr. Joseph Fewer, GroGenesis CEO, comments, "The response from Central America has been extremely positive and we look forward to offering this presentation to an audience of key strategic leaders from across the region. We want to thank Peter Zimeri, our local representative for his extraordinary assistance, and we look forward to meeting with the various grower/operators as well as industry and government representatives who have already indicated a desire to participate. We anticipate a very productive and informative meeting and thank everyone in advance for their time and interest."
Additional details of the Company's business, finances, appointments and agreements can be found in its ongoing filings which forms part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov.
About AgraBlast and AgraBurst
AgraBlast is a liquid broad-spectrum algaecide, fungicide and bactericide that works on contact and leaves behind no residue making it ideal for use in agricultural industries. AgraBlast provides disease protection against bacterial inoculums and fungal spores, including powdery and downy mildew. AgraBurst enhances efficient photosynthesis, stimulates higher plant sugar levels and boosts the uptake of water, minerals and key nutrients resulting in larger, healthier and more productive plants. Used as directed, these products provide control for organic and conventional growers of coffee plants, bananas, sugar cane, rubber trees, fruit trees, leafy vegetables, tomatoes, potatoes and many others. The products are also effective when used on sod, cut flowers, grasses, woody ornamentals, and more.
About GroGenesis, Inc. (OTCBB: GROG)
GroGenesis aims to become a leading producer of natural plant growth health technologies. The Company's 'AgraBurst' is neither a fertilizer nor herbicide. The product is a plant growth technology blended from processed extracts of natural plant materials that directly improves the positive effects of commercial fertilizers and available nutrients. GroGenesis latest product, "AgraBlast" is an eco-friendly, non-toxic alternative to synthetic fungicides. When used in combination, the Company offers an innovative solution for the control of plant pathogenic fungi and for plant remediation and stimulation of yields. Find out more at www.grogenesis.com.
IntelGenx (TSXV:IGX) (OTCQX:IGXT) Provides Update on Sales of Forfivo XL(R)
SAINT LAURENT, Quebec, Feb. 23, 2015 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx", or the "Company") today provided an update on sales and marketing activities for Forfivo XL®, the Company's first FDA-approved product that was launched in the USA in October 2012 under an exclusive commercialization agreement with Edgemont Pharmaceuticals LLC ("Edgemont").
According to Symphony Health Solutions, gross sales of Forfivo XL® totaled $8.9 million in the year ending December 31st, 2014, an increase of 230% compared with sales of $2.7 million in the preceding year. The number of Forfivo XL® prescriptions filled increased by 123% from approximately 16,761 in 2013 to 30,378 in 2014. The average month-on-month growth rate of Forfivo XL® throughout 2014 exceeded 9%.
"We are extremely pleased with the growth of Forfivo XL® throughout 2014 and we believe that this growth will continue, especially as Edgemont increased its salesforce threefold in mid-December, 2014" stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "The marketing and sales efforts that our partner, Edgemont Pharmaceuticals, has invested in the commercialization of Forfivo XL® have ensured that a more convenient and safe alternative for patients requiring high-dose anti-depressant therapy is widely available in the US. Forfivo XL® generated in excess of $1.1 million (unaudited) of revenue for IntelGenx in 2014 and we anticipate significantly higher revenue from the product in 2015."
Forfivo XL® is indicated for treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL® is bupropion, the same active ingredient used in the well-known antidepressant product: Wellbutrin XL®.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Highbank Resources (TSX VENTURE: HBK) SPN Quarry Project & LNG Updates
VANCOUVER, BC--(Marketwired - February 19, 2015) - Highbank Resources Ltd. (the "Company"), (TSX VENTURE: HBK).
Victor N. Bryant, CEO/President reports: "A crew at Swamp Point North ("SPN") has recently returned to the site and is active clearing snow, upgrading and maintaining roads, and logging/clearing further quarry area for stockpiles. Khtada Environmental Services LP monitoring personnel were on site last week taking samples in compliance with our Mines Act Permit. A supply barge left the Port of Prince Rupert, Wednesday morning to arrive later today. The barge manifest included specific winter weather materials -- chains for the 30 ton rock trucks, corks/spikes for the bulldozer, winter camp supplies and additional large diameter culvert pipes for appropriate road and drainage use."
"I will be arriving at the SPN project today with Stan Spletzer (V.P. of Aggregate Operations) and Bill Faulhaffer (Journeyman Quarry Operations Manager), who will be in charge of the day to day operations of our quarry operation. Also accompanying us will be a Micon International engineer to commence work on the PEA study as per our February 16, 2015 new release."
"The SPN project crew was making ready to move on site for February 1, 2015 when a significant snow event occurred. Presently, there is about three feet of snow on site, but we can see no reason that we, as a Canadian Company are going to stop progress for snow. Additional crews are expecting to arrive to SPN Friday, February 20th to further enhance roads; excavate discharge settling ponds for the wash plant; commission the wash plant, move the jaw crusher to optimal positioning and commission the jaw crusher; install culverts for further water runoff management; expand shoreline area for stockpiling and shipping finished aggregates; and last but not least, commission the quarry and plant to process through the first of many barge loads of aggregate for 2015 anticipated sales."
LNG Developments:
'Northern View' - Prince Rupert news….. Prince Rupert LNG (a partnership with BG Canada and The Westcoast Connector Gas Transmission Project) have opened a community engagement office at 610 - 2nd Ave. in Prince Rupert, B.C. and welcomes you to come by and visit them to discuss their Ridley Island LNG project or visit their website at www.princerupertlng.ca.
Also, Aurora LNG (a joint venture between Nexen Energy ULC -- a CNOOC Limited company, INPEX Corporation and JGC Exploration Canada Ltd.) will be opening their community office at 344, 2nd Avenue West in Prince Rupert in early March or visit their website at www.auroralng.com. For more information about the B.C. environmental assessment process, go to www.eao.gov.bc.ca. A Community Information Open House has taken place on February 18th in Prince Rupert in addition to the BC Environmental Assessment Office (BCEAO)-led public comment periods that are part of the environmental assessment process. Aurora LNG is currently studying the viability of constructing and operating a LNG facility and marine terminal, near Prince Rupert, on Digby Island. Feedback received from the Open House will be considered by the Aurora Project team, along with environmental, technical and socio-economic considerations.
On behalf of the Board of Directors of HIGHBANK RESOURCES LTD.
"Victor N. Bryant"
Victor N. Bryant, CEO/President
iHookup Social (HKUP) Announces Planned Reverse Stock Split, to Pursue Return to OTC Markets' OTCQB Exchange
CAMPBELL, CA--(Marketwired - Jan 9, 2015) - iHookup Social, Inc. (OTC PINK: HKUP), a fully reporting public company that develops a mobile/social app enabling singles, groups and the socially active to connect quickly, offering local, real life 'hook-up' opportunities, is pleased to announce that it will petition for relisting on OTC Market's OTCQB exchange following a 100-for-1 reverse stock split.
"After evaluating all available options, management has determined that the most effective course of action for the Company is a 100-1 reverse stock split that we hope will allow for a swift return to OTCMarkets' OTCQB exchange," stated Robert Rositano, Jr. CEO, iHookup Social. "We believe that our departure from the OTCQB has had a demonstrably adverse effect on our company and that it is essential that we return to a senior exchange where we believe our fully reporting status and corporate achievements are more widely viewed and appreciated."
Pending the review of the Securities Exchange Commission, shareholders of record at the end of trading approximately 30 to 60 days from today will be affected by the 100-1 reverse stock split. When the market opens on or about this date every one-hundred (100) shares of issued and outstanding common stock will be converted into one (1) share of common stock. All fractional shares created by the reverse stock split will be rounded to the nearest whole share.
For a current Investor Presentation please visit: http://www.ihookupsocial.com/overview/
From time to time, iHookup Social will provide market updates, news and additional information via its website www.ihookupsocial.com, the Company's Facebook page and others www.facebook.com/ihookupnow
iHookup Social, Inc.
iHookup Social, Inc. is a mobile Social Dating App positioned at the intersection of dating, social media and location-based connections.
About iHookup Social:
iHookup Social is a mobile -- social app that provides singles, groups and the socially active a way to connect quickly and efficiently with local, real life 'hook-up' opportunities.
The iHookup difference: An app that is all about virtual meetings translating to real-life interactions, facilitating the connection and then offering-up locally relevant hot spots and locations to engage with these new connections. An app meeting is the first step, with Venues completing a circle of service that allows iHookup Social to be both matchmaker and concierge. This combination provides a no brainer approach to "Hooking up," as well as a unique opportunity for consumer brands to offer incentives to a growing network of socially active singles and mobile users.
iHookup Social... where real people make real connections... and where real businesses pay to be their host. www.ihookupsocial.com
iHookUp Social (HKUP) Completes Phase I Urban Airship Integration and Submits to Apple App Store
Leading Industry Provider to Enhance Monetization Opportunities
CAMPBELL, CA--(Marketwired - Dec 23, 2014) - iHookup Social, Inc. (OTC PINK: HKUP), a fully reporting public company and mobile/social app that enables singles and the socially active to instantly connect with local, real life 'hook-up' opportunities, is pleased to announce that it has submitted its next generation version of its iHookup Social app to the Apple App Store. The app breaks new ground for iHookup and its members as an array of new features based primarily around member-to-member connectivity will be deployed upon approval, boosting efforts to monetize hookup "Hot Spots" or locations and add advertising sponsors to the existing business model.
"This version of our app demonstrates what we believe is a critical brand separator for iHookup Social and further leverages our growing user base to extend our revenue model with the addition of sponsorship and advertising," stated Robert Rositano, CEO, iHookup Social. "Like others in the mobile/social dating space, we are intent on building upon our asset and our asset is users, facilitating connections for users, providing local hookup Hot Spots and continuing to advance our features allows us to scale. We see our customer lifecycle as perpetual and look to provide exciting opportunities for users well beyond the initial co
This new app immediately enhances the connectivity and quality of interaction we will now have with and among our user network," added Rositano. "But they also set the structural stage for a feature that we believe will provide a significant differentiation of iHookup Social in the early stages of 2015. Stay tuned."
The latest app's feature set includes the following:
•NEW - Chat experience - Share Photos and Videos -- users can now share both photos and videos with other users while in chat
•NEW - Hookup Spots - Updated nearby locations, events, restaurants, clubs -- available to share with other users while in chat mode
•NEW - User experience Enhancements
•NEW - Menus -- left and right menu has been slimmed down for a more focused user experience
•NEW - Phase 1 Urban Airship feature implementation
•NEW - Grid and Location Map view options have been reduced in order to provide a more focused core experience for users
•App side performance optimizations
•Server performance optimizations
•User reported bug fixes
From time to time, iHookup Social will provide market updates, news and additional information via its website www.ihookupsocial.com, the Company's Facebook page and others www.facebook.com/ihookupnow.
About Urban Airship
Urban Airship enables brands to build relationships with their constantly connected customers through Mobile Relationship Management. Its solutions streamline the creation, delivery and management of highly targeted cross-platform mobile push messages, in-app messages, landing pages, Apple Passbook passes and Google Wallet cards. With billions of messages and tens of thousands of passes delivered each month, Urban Airship's technology sparks exceptional consumer experiences, drives app engagement and increases customer loyalty and lifetime value for the world's largest retail, media & entertainment, sports and travel & hospitality brands. For more information, visit www.urbanairship.com and follow us on Twitter @urbanairship.
About iHookup Social:
iHookup Social is a mobile -- social app that provides singles, groups and the socially active a way to connect quickly and efficiently with local, real life 'hook-up' opportunities.
The iHookup difference: An app that is all about virtual meetings translating to real-life interactions, facilitating the connection and then offering-up locally relevant hot spots and locations to engage with these new connections. An app meeting is the first step, with Venues completing a circle of service that allows iHookup Social to be both matchmaker and concierge. This combination provides a no brainer approach to "Hooking up," as well as a unique opportunity for consumer brands to offer incentives to a growing network of socially active singles and mobile users.
iHookup Social... where real people make real connections... and where real businesses pay to be their host. www.ihookupsocial.com
Las Vegas From Home’s (TSX-V: LVH) Software Deployed on Carnival Cruise lines
Guests will be able to wager on their personal mobile devices throughout the ship while in international waters
Vancouver, British Columbia (FSCwire) - Las Vegas From Home.com Entertainment Inc. (the “Company” or “LVFH”) (TSX-V: LVH) (US OTC Pink Sheets: LVFHF) (Frankfurt: LVH). LVFH is pleased to announce that Carnival Corporation has started offering its guests the ability to wager for real money on their mobile devices throughout their ships while in international waters.
The service is already in successful operation on the Carnival Breeze and Carnival Freedom and will be launched shortly on the Carnival Sunshine, with additional installations pending for the Princess Cruises and Holland America Line brands.
The game offerings available on Carnival’s Mobile Casino include a host of best-in-class poker, slot, and table-game content from Bally, LVFH, Play’n’Go and PokerTek. Specifically, LVFH is providing the more popular, well-known games including blackjack, Fun 21, American roulette and Texas Hold’em poker, with additional content to be provided by LVFH in 2015.
“Our games are amongst the most popular played on the ship, and for that reason, the initial results are very promising,” said Jake Kalpakian, Chief Executive Officer of LVFH. “As Carnival increases exposure of the gaming platform to their customers and scales the gaming operation to additional cruise ships, we expect revenue to increase swiftly.
LVFH software utilizes a technology known as HTML5, which allows it to be played within a mobile browser, a downloadable iOS or Android app, or in the browser of a PC or Mac. Special techniques are employed to enhance the user experience, such as the ability to play in portrait or landscape mode on any device, and dynamically adjusting the game to any screen size without compromising game play. This flexibility allows LVFH games to be deployed to any major platform or device without modification, which is an attractive quality to many iGaming operators.
Mr. Kalpakian further stated “the mobile technology platform we created works extremely well on cruise ships, but we also realized that it is perfectly suited toward hotel resorts as well. We are currently in discussions with several hotel resort chains in Mexico to use our platform.”
Mr. Marty Goldman, Senior Vice President of Global Casino Operations for Carnival Corporation said “We’re excited to partner with Bally, LVFH and other content providers to offer our guests a new and thrilling entertainment option that will enhance their experience aboard our ships.” Mr. Goldman further stated “Bally is a leader in the mobile gaming space and offered the best solution for our needs. For the first time, we’re bringing the casino to our guests so they can play their favorite games on their mobile devices when they are lounging by the pool, relaxing in their rooms, or anywhere else onboard.”
About Carnival Corporation & plc
Carnival Corporation & plc is the largest cruise company in the world, with a portfolio of cruise brands in North America, Europe, Australia and Asia, comprised of Carnival Cruise Lines, Holland America Line, Princess Cruises, Seabourn, AIDA Cruises, Costa Cruises, Cunard, Ibero Cruises, P&O Cruises (Australia) and P&O Cruises (UK).
Together, these brands operate 101 ships totaling 212,000 lower berths with seven new ships scheduled to be delivered between 2014 and 2016. Carnival Corporation & plc also operates Holland America Princess Alaska Tours, the leading tour companies in Alaska and the Canadian Yukon. Traded on both the New York and London Stock Exchanges, Carnival Corporation & plc is the only group in the world to be included in both the S&P 500 and the FTSE 100 indices.
About Bally Technologies, Inc.
Founded in 1932, Bally Technologies (recently acquired by Scientific Games Corporation (NASDAQ: SGMS) provides the global gaming industry with innovative games, table game products, systems, mobile, and iGaming solutions that drive revenue and provide operating efficiencies for gaming operators. For more information, please visit http://www.ballytech.com. Connect with Bally on Facebook, Twitter, YouTube, LinkedIn, and Pinterest.
About Las Vegas From Home.com Entertainment Inc.
LVFH is a poker, casino and bingo software provider which has been in operation since 1999. LVFH develops and licenses a Remote Gaming System to add gaming content to existing websites, as well as an Interactive Gaming Platform which provides an end-to-end iGaming solution for operators. LVFH’s lengthy track record in gaming software development has made LVFH one of the leading software developers in the industry. Visit us at http://www.lvfh.com
Eternity Healthcare Inc. (OTC:ETAH) FDA Approves a Safer Way to Administer Vaccines
PHOENIX and VANCOUVER, British Columbia, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Eternity Healthcare Inc. (OTC:ETAH), a medical device and diagnostic company with advanced technologies in Needle-Free Injection system, announced today that the Food and Drug Administration (FDA) has given 510(K) clearance to West Pharmaceutical Services, Inc. to start producing Needle-stick Guards to help the Medical Professionals administer vaccines in a safer way.
"EXTON, Pa., Nov. 11, 2014 -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that the NovaGuard SA (Staked-needle Automatic) safety system has received 510(k) clearance from the United States Food and Drug Administration. The NovaGuard SA safety system helps reduce the risk of needle-stick injuries by shielding the exposed needle of a prefilled syringe after use."
"The FDA is making great progress in the Medical field, buy focusing on safety, for not only for the Doctors but the patient," Dr. Salari, President & CEO of Eternity Healthcare Inc. stated. He went on by saying, "We believe the best solution, rather than a Needle Guard, would be the Needle-Free Injection system such as ours, the Comfort-in™. Our product uses no needles to administer vaccines, thus eliminating any chance for accidental poking and cross contamination. Focusing on products that make everyone safer should be a priority for not only the FDA, but Medical Field."
About Eternity Healthcare, Inc.
Eternity Healthcare Inc. or the "Company" (OTC:ETAH) is a healthcare company with technologies in medical devices and diagnostics. Our most advanced product is a needle-free injection system known as Comfort-inTM. Our products are sold to healthcare professionals, for use in physicians' offices, pharmacies, and to consumers directly. For more information on Eternity Healthcare, visit the Company's website: www.eternityhealthcare.com
Eternity Healthcare Inc. will also provide market and news updates via its social media sites, so please visit one of these sites for more information:
Facebook Page: www.Facebook.com/EternityHealthcare
Twitter Page: www.twitter.com/EternityHealth
Instagram Page: www.instagram.com/EternityHealthcare
YouTube Channel: Youtube.com/user/EternityHealthcare1
Seeking Alpha Page: www.seekingalpha.com/user/33690795/profile
StockTwits Page: www.stocktwits.com/eternityhealthcare
Pinterest Page: www. pinterest.com/Eternity_Health
Google Plus Page: plus.google.com/108722464621793491752
iHookup Social (HKUP) Adds Urban Airship Technology to Next App Release
Leading Industry Technology Provider to Enhance Communication and Monetization Opportunities
CAMPBELL, CA--(Marketwired - Dec 8, 2014) - iHookup Social, Inc. (OTC PINK: HKUP), a fully reporting public company that develops a mobile/social app enabling singles and the socially active to connect quickly and efficiently, offering local, real life 'hook-up' opportunities, is pleased to announce that it has entered into an agreement with Urban Airship, a global leader in mobile relationship management
This relationship provides the company a significant boost in strategy, implementation and deployment of advanced mobile engagement capabilities for the iHookup Social app. Urban Airship's reputation and case studies show proven market metrics in both improved interaction with users and increased monetization opportunities through the deployment of their technology.
iHookup anticipates a Phase1 release of the Urban Airship technology integration to be released for App Store submission in early December of 2014. Urban Airship currently provides technology to several modern dating market leaders.
"We are extremely pleased by the opportunity to work with the bright minds and proven talent at Urban Airship," stated Robert Rositano Jr., CEO, iHookup Social. "Not only are we integrating a technology suite that I believe will be catalytic to future successes, we are also given access to their strategic consultants who will work hand-in-hand with our marketing team to seamlessly adapt all the best engagement touch points for increased user interaction and monetization.
"Most important to this relationship is the localized tracking and offer side which advances our "Venue Recommendations" far ahead of current capabilities, setting the stage for what we believe to be a real "Game Changing Feature" to be announced in 2015," added Rositano.
From time to time, iHookup Social will provide market updates, news and additional information via its website www.ihookupsocial.com - http://www.ihookupsocial.com/overview the Company's Facebook page and others www.facebook.com/ihookupnow.
Related Quotes
•HKUP0.0014-6.67%
iHookup Social, Inc.? Watchlist
0.0014-0.0001(6.67%)
OTC MarketsFri, Dec 5, 2014 3:58 PM EST
•IHOOKUP SOCIAL, INC. Financials
EDGAR Online Financials 11 days ago
•IHOOKUP SOCIAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online 14 days ago
More
About Urban Airship
Urban Airship enables brands to build relationships with their constantly connected customers through Mobile Relationship Management. Its solutions streamline the creation, delivery and management of highly targeted cross-platform mobile push messages, in-app messages, landing pages, Apple Passbook passes and Google Wallet cards. With billions of messages and tens of thousands of passes delivered each month, Urban Airship's technology sparks exceptional consumer experiences, drives app engagement and increases customer loyalty and lifetime value for the world's largest retail, media & entertainment, sports and travel & hospitality brands. For more information, visit www.urbanairship.com and follow us on Twitter @urbanairship.
About iHookup Social:
iHookup Social is a mobile -- social app that provides singles, groups and the socially active a way to connect quickly and efficiently with local, real life 'hook-up' opportunities.
The iHookup difference: An app that is all about virtual meetings translating to real-life interactions, facilitating the connection and then offering-up locally relevant hot spots and locations to engage with these new connections. An app meeting is the first step, with Venues completing a circle of service that allows iHookup Social to be both matchmaker and concierge. This combination provides a no brainer approach to "Hooking up", as well as a unique opportunity for consumer brands to offer incentives to a growing network of socially active singles and mobile users.
iHookup Social... where real people make real connections... and where real businesses pay to be their host. www.ihookupsocial.com
iHookup (HKUP) Reaches 445,000 Registered Users, Provides Updated Investor Presentation
The Company's Milestone Goal of 500,000 Downloads Draws Closer
CAMPBELL, CA--(Marketwired - Dec 2, 2014) - iHookup Social, Inc. (OTC PINK: HKUP), a fully reporting public company that develops a mobile/social app that enables singles, groups and the socially active to connect quickly and efficiently, offering local, real life 'hook-up' opportunities, is pleased to provide user growth statistics for November of 2014, along with an updated Investor Presentation
For the month of November, the Company continued its user acquisition strategy for the fourth quarter by adding 48,665 new downloads of the iHookup Social app, as reported by the Apple App Store, as well as adding additional registered users to its existing base. To date, the company has now surpassed 445,000 registered users on the iHookup Social network.
Additionally, the Company has prepared an updated and current Investor Presentation for public viewing. It is available at: http://www.ihookupsocial.com/overview/
The presentation includes updated slides addressing insider sales, cost of acquisition, and results of its marketing efforts that the public may find useful in better understanding the Company's focus on building the asset, which is its "User Base," as well as the past, present and future growth / valuation strategy.
"We are very pleased to look back on a year of great progress for the company and to now provide the market with our most current market statistics as well. Our updated presentation provides some great visual explanation of what we have seen in app growth, conversion and overall performance as we continue releasing advancements to the app, as well as adapting the business for substantial growth in 2015," stated Robert Rositano Jr., CEO, iHookup Social. "It was another month that met our expectations for the app, especially considering our planned reduction in advertising expense for the period. App downloads and ranking fluctuations are often indicators of testing new pricing and marketing strategy, which will prove short-lived. I firmly believe the value of iHookup Social is tied to our number one asset, 'Users', and building our asset as we have adapted our vision to the technology is proving to be the correct path."
January
7,406 New Downloads
120,148 Total Registered Users
February
6,547 New Downloads
124,588 Total Registered Users
March
16,599 New Downloads
137,743 Total Registered Users
Related Quotes
•
HKUP0.0018-25.00%
iHookup Social, Inc.? Watchlist
0.0018-0.0006(25.00%)
OTC MarketsMon, Dec 1, 2014 3:58 PM EST
•IHOOKUP SOCIAL, INC. Financials
EDGAR Online Financials 5 days ago
•IHOOKUP SOCIAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online 8 days ago
More
April
43,207 New Downloads
164,632 Total Registered Users
May
67,054 New Downloads
212,528 Total Registered Users
June
75,065 New Downloads
257,316 Total Registered Users
July
80,283 New Downloads
308,167 Total Registered Users
August
86,207 New Downloads
353,440 Total Registered Users
September
89,970 New Downloads
386,694 Total Registered Users
October
58,852 New Downloads
422,439 Total Registered Users
November
48,665 New Downloads
445,818 Total Registered Users
From time to time, iHookup Social will provide market updates, news and additional information via its website www.ihookupsocial.com, the Company's Facebook page and others www.facebook.com/ihookupnow
iHookup Social, Inc.
iHookup Social, Inc. is a mobile Social Dating App positioned at the intersection of dating, social media and location-based connections.
About iHookup Social:
iHookup Social is a mobile -- social app that provides singles, groups and the socially active a way to connect quickly and efficiently with local, real life 'hook-up' opportunities.
The iHookup difference: An app that is all about virtual meetings translating to real-life interactions, facilitating the connection and then offering-up locally relevant hot spots and locations to engage with these new connections. An app meeting is the first step, with Venues completing a circle of service that allows iHookup Social to be both matchmaker and concierge. This combination provides a no brainer approach to "Hooking up", as well as a unique opportunity for consumer brands to offer incentives to a growing network of socially active singles and mobile users.
iHookup Social... where real people make real connections... and where real businesses pay to be their host. www.ihookupsocial.com
IntelGenx (IGXT) Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
SAINT LAURENT, Quebec, Dec. 2, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont") has exercised its right to extend the license for the exclusive marketing of Forfivo XL® 450 mg tablets.
Under the terms of the extension, Edgemont will retain certain exclusive rights to market and sell Forfivo XL® in the U.S. In exchange, IntelGenx will receive a seven-figure milestone payment. All other financial obligations contained in the license agreement entered into by Edgemont and IntelGenx in February 2012, specifically launch-related and sales milestones, together with the contractual royalty rates on net sales of the product, remain in effect.
"We are very pleased that Edgemont will continue to be the exclusive commercialization partner of Forfivo XL," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We have witnessed significant progress in sales of the product during recent months, with monthly sales exceeding $1 million in October and we believe that this growth will continue. We are confident that our partner, Edgemont Pharmaceuticals, has and will continue to make every effort to maximize the potential of Forfivo XL in the U.S."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
BLUE RIVER RESOURCES LTD. ( TSX.V: BXR ) (OTC: BRVRF) UPDATES EXPLORATION PLAN FOR CASTLE PROJECT AND MAZAMA COPPER DEPOSIT
Dec 01, 2014
Vancouver, BC – November 29, 2014: Blue River Resources Ltd. ( TSX.V: BXR ) (OTC: BRVRF)("Blue River" or “the Company”) announces exploration results from a recent surface sampling program on the Castle Copper Project and an updated exploration plan for the 2015 field season for the Company's Mazama Copper Deposit.
CASTLE COPPER PROJECT
The Company recently conducted a surface sampling program on the Castle Copper Project, located near Princeton BC, and approximately 25 km north of the Copper Mountain Mine.
Copper grades from 24 rock grab samples ranged from a high of 2.2% copper on surface and averaged 0.5% Cu. The sampled area is from a zone of highly fractured and sheared Nicola Group volcanic rocks.
Future exploration plans on the Castle Project call for an IP survey to the north and west of previously drilled areas of the Castle Project with the emphasis on locating porphyry copper mineralization drill targets.
MAZAMA COPPER DEPOSIT
Permitting for the upcoming drill program on the Company’s 100% owned Mazama Copper Deposit is continuing, with field work by the US Forest Service having been completed. The Company estimates receiving the permit in the first quarter of 2015.
The permit was delayed by the largest wildfire in Washington State’s history, in the eastern Methow Valley. The Mazama Copper Deposit is located in the western part of the Methow Valley, Okanogan County, WA, approximately 25 km south of the Canada/US border in North Central Washington, 143 km northeast of Seattle. Both the Castle Project and Mazama Copper Deposit are situated on the southern extension of the Quesnel Trough copper belt, one of the most prolific copper producing areas in North America.
Quintana Minerals Corp., in 1975, calculated an historical resource* on the Mazama property of 149 million tons grading 0.36% copper and 0.01% molybdenum, or approximately 1 billion pounds of copper. Although historic adits that were explored for gold mineralization are located on the property, no gold assays were reported.
The Company has completed geological mapping and sampling, a LIDAR survey, topographic mapping and located historic drill holes.
Blue River will conduct a minimum 2,000 meters (6,000 feet) of diamond drilling, to confirm previously delineated areas of mineralization, as well as test new potential areas of mineralization developed from the 2014 exploration and staking program. The objective of the 2015 exploration program is to confirm and expand the historic copper mineralization located within the Mazama Copper Deposit. The Company has paid a 50% deposit for drilling and geological work for this exploration program.
*A qualified person has not done sufficient work to classify the historical estimate as current mineral resources. Blue River is not treating the historical estimate as current mineral resources.
The technical information contained in this news release was reviewed and approved by Paul D. Gray, P. Geo, a qualified person as defined under National Instrument 43-101.
ON BEHALF OF THE BOARD
BLUE RIVER RESOURCES LTD.
BLUE RIVER RESOURCES LTD. ( TSX.V: BXR ) (OTC: BRVRF) UPDATES EXPLORATION PLAN FOR CASTLE PROJECT AND MAZAMA COPPER DEPOSIT
Dec 01, 2014
Vancouver, BC – November 29, 2014: Blue River Resources Ltd. ( TSX.V: BXR ) (OTC: BRVRF)("Blue River" or “the Company”) announces exploration results from a recent surface sampling program on the Castle Copper Project and an updated exploration plan for the 2015 field season for the Company's Mazama Copper Deposit.
CASTLE COPPER PROJECT
The Company recently conducted a surface sampling program on the Castle Copper Project, located near Princeton BC, and approximately 25 km north of the Copper Mountain Mine.
Copper grades from 24 rock grab samples ranged from a high of 2.2% copper on surface and averaged 0.5% Cu. The sampled area is from a zone of highly fractured and sheared Nicola Group volcanic rocks.
Future exploration plans on the Castle Project call for an IP survey to the north and west of previously drilled areas of the Castle Project with the emphasis on locating porphyry copper mineralization drill targets.
MAZAMA COPPER DEPOSIT
Permitting for the upcoming drill program on the Company’s 100% owned Mazama Copper Deposit is continuing, with field work by the US Forest Service having been completed. The Company estimates receiving the permit in the first quarter of 2015.
The permit was delayed by the largest wildfire in Washington State’s history, in the eastern Methow Valley. The Mazama Copper Deposit is located in the western part of the Methow Valley, Okanogan County, WA, approximately 25 km south of the Canada/US border in North Central Washington, 143 km northeast of Seattle. Both the Castle Project and Mazama Copper Deposit are situated on the southern extension of the Quesnel Trough copper belt, one of the most prolific copper producing areas in North America.
Quintana Minerals Corp., in 1975, calculated an historical resource* on the Mazama property of 149 million tons grading 0.36% copper and 0.01% molybdenum, or approximately 1 billion pounds of copper. Although historic adits that were explored for gold mineralization are located on the property, no gold assays were reported.
The Company has completed geological mapping and sampling, a LIDAR survey, topographic mapping and located historic drill holes.
Blue River will conduct a minimum 2,000 meters (6,000 feet) of diamond drilling, to confirm previously delineated areas of mineralization, as well as test new potential areas of mineralization developed from the 2014 exploration and staking program. The objective of the 2015 exploration program is to confirm and expand the historic copper mineralization located within the Mazama Copper Deposit. The Company has paid a 50% deposit for drilling and geological work for this exploration program.
*A qualified person has not done sufficient work to classify the historical estimate as current mineral resources. Blue River is not treating the historical estimate as current mineral resources.
The technical information contained in this news release was reviewed and approved by Paul D. Gray, P. Geo, a qualified person as defined under National Instrument 43-101.
ON BEHALF OF THE BOARD
BLUE RIVER RESOURCES LTD.
RedHill Biopharma and IntelGenx (IGXT) Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
•The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT™ (RHB-103) and initiated its formal review of the application on November 25, 2014
•RedHill and IntelGenx continue to work with the FDA to resolve the remaining Chemistry, Manufacturing and Controls (CMC) issues and secure a compliant source of the raw material, in order to advance potential FDA approval of the U.S. New Drug Application submitted by the companies
•RIZAPORT™ oral thin film formulation of rizatriptan for acute migraines presents a potentially attractive therapeutic alternative for many migraine patients, including those suffering from migraine-related nausea, due to its convenient dosing, lack of need for water intake and pleasant flavoring
TEL-AVIV, Israel, Dec. 1, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced, together with IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"), a Canadian drug delivery company focused on oral drug delivery, that the German Federal Institute for Drugs and Medical Devices (BfArM) validated the Marketing Authorization Application (MAA) for RIZAPORT™, an oral thin film formulation of rizatriptan for acute migraines, and has initiated the formal review process of the application on November 25, 2014. BfArM's potential feedback regarding the MAA is expected during the second half of 2015.
RIZAPORT™ oral thin film does not require the patient to swallow a pill or consume water and presents a potentially attractive therapeutic alternative for many migraine patients, including those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population1.
The MAA was submitted under the European Mutual Recognition Procedure (MRP) with Germany as the reference member state and Luxemburg as the Concerned Member State. The submission is supported by several studies and follows a positive scientific advice meeting with the BfArM.
RedHill and IntelGenx submitted a New Drug Application (NDA) to the FDA in March 2013 seeking marketing approval of RIZAPORT™ in the U.S. Following a complete response letter (CRL) received from the FDA in February 2014, which raised questions primarily related to CMC, RedHill and IntelGenx reported that they believe that FDA approval of the RIZAPORT™ NDA is subject to the satisfactory resolution of the remaining CMC questions, as well as securing a compliant source of the raw material. Accordingly, the companies continue to work with the FDA in order to address and resolve all remaining CMC questions and to secure a compliant source of the raw material.
About RIZAPORT™ (RHB-103):
RIZAPORT™ is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. Marketing applications for RIZAPORT™ have been filed both in the U.S. (NDA filed in March 2013) and in Europe (MAA filed in October 2014). Rizatriptan is considered one of the most effective oral triptans, a class of molecules that constrict blood vessels in the brain to relieve swelling and other migraine symptoms. The worldwide annual sales of triptans were estimated to have exceeded $1 billion in 20132.
RIZAPORT™ is based on IntelGenx' proprietary "VersaFilm™" technology. It dissolves rapidly and releases its active ingredient in the mouth, leading to an efficient absorption of the drug through the gastro intestinal tract. The administration method of the RIZAPORT™ oral thin film which does not require the patient to swallow a pill or consume water, along with its pleasant flavoring, presents a potentially attractive therapeutic alternative for many migraine patients, including those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population3.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) is an emerging Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. RedHill's current pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection, with an ongoing first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease, with an ongoing first Phase III study; (iii) RHB-102 - a once-daily oral pill formulation of ondansetron with a Phase III study in the U.S. for acute gastroenteritis and gastritis and a planned European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting (iv) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) MESUPRON™ - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; (vi) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (vii) RIZAPORT™ (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA currently under discussions with the FDA and a European marketing application submitted in October 2014; and (viii) RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol. For more information please visit www.redhillbio.com.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
IntelGenx (IGXT) Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
Saint Laurent, Quebec--(Newsfile Corp. - November 25, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL® 450 mg tablets.
The Company will hold a call to discuss details of the settlement on Wednesday, December 3, 2014 at 10:00 AM ET. A live broadcast of the call will be available through the Company's website at www.intelgenx.com. Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
Conference dial-in: 877-269-7756877-269-7756
International dial-in: 201-689-7817201-689-7817
Conference Call Name: IntelGenx Management Update Call
Webcast Registration: CLICK HERE
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Highbank (TSX VENTURE: HBK) Comments on Landmark B.C. LNG News -- Exxon, Nisga'a, PRGT, JAPEX
VANCOUVER, BC--(Marketwired - November 25, 2014) - Highbank Resources Ltd. (the "Company"), (TSX VENTURE: HBK) (FRANKFURT: V7O).
Victor N. Bryant, CEO/President comments, "I am pleased to list and comment on recent news stories and events that could have a direct impact and/or are relevant to the development of the Swamp Point North operation."
20.11.14 Nisga'a Nation signs onto LNG project
"The opportunity to be an active player in the LNG industry is the kind of opportunity for which our elders struggled for over a century, so we could achieve sustainable prosperity for our people into the next century, our elders have told us, now is the time to be bold and move forward." -- Nisga'a Nation President, Mitchell Stevens.
Victor N. Bryant, CEO comments, "I commend the elected officials and elders of the Nisga'a Nation for an agreement that helps ensure a prosperous future for the Nisga'a people. The Nisga'a are our neighbors and Highbank will always support them in their endeavors." Story: http://ow.ly/EDwz3
20.11.14 Exxon Mobil Canada joins B.C. LNG Alliance
"The alliance states Exxon Mobil Canada has a licence to export as much as 30 million tonnes of LNG annually and the company has entered an option agreement with the City of Prince Rupert for a site at Tuck Inlet."
CBC story: http://ow.ly/EDiO6 Area Map: http://ow.ly/EDdTL
This news is well received by Highbank, as this LNG site is yet another potential major location for sales of the Company's construction aggregates.
14.11.14 Site Inspection
Our director, Mr. Jim Place met on site with representatives of an International engineering firm tasked with identifying viable sources of construction aggregate for an unnamed multinational energy corporation. Mr. Place came in from Stewart, B.C. by company workboat to meet the Engineers who flew in to the site by helicopter. The inspection was completed and Mr. Place will be providing details of the initial sample test reports to the engineering firm.
13.11.14 JAPEX Breaks ground on its "Soma Port" LNG terminal -- Fukushima Prefecture
Vic Bryant comments, "The official JAPEX press release affords some very telling insights as to the production timing for the Petronas led PNW LNG consortium (JAPEX 10% -- 12 million ton stake). The press release specifically references the source of the LNG coming to this new terminal as from the Port of Prince Rupert, although they further stated the terminal will be receiving LNG from other un-named sources. Scheduled start of operations, March 2018."
Official JAPEX English version news release with groundbreaking ceremony photos. http://ow.ly/EDaCf
12.11.14 City of Prince Rupert Outlines plans for Camp sites
The City of Prince Rupert has singled out potential sites for a construction workers' camp and storage/material handling area. "This is a zone to facilitate activities within our zoning bylaw that will take place for a finite period of time," Robert Long, Prince Rupert city manager, said during the Nov. 3 council meeting.
News story here: http://ow.ly/EDo5W
11.11.14 Prince Rupert Gas Transmission ("PRGT") signs milestone agreement with the Nisga'a Nation
"First Nations are going to look to this agreement as a concrete example of what can be done between a company like TransCanada and First Nations". -- See more and video at: http://ow.ly/EDryw
11.25.14 Upcoming Event
Victor N. Bryant comments, "Highbank's Directors will be meeting with a European sub sea pipeline laying company to discuss opportunities for providing aggregates for bedding purposes. It would seem likely given the frequency and timing of the above events that a major LNG project starting is soon to be announced."
On behalf of the Board of Directors of HIGHBANK RESOURCES LTD.
"Victor N. Bryant"
Victor N. Bryant,
CEO/President
Premier Holding Corporation (PRHL) to Launch Investor and Industry Awareness Campaign for 2015
TUSTIN, CA , United States, via ETELIGIS INC., 11/24/2014 - - Premier Holding Corporation, (OTCQB: PRHL), parent of its energy supplier (Lexington Power & Light) a power reseller in deregulated markets (The Power Company), and a reseller of energy efficiency technologies (Energy Efficiency Experts), is pleased to announce that it will lead a comprehensive, coordinated campaign to educate professional investors and industry experts on Premier's "Everything Energy" strategy. CEO Randall Letcavage will work with financial industry organizations, professionals, and analysts to deliver a message that explains Premiers plans and the desired effect from the integration of its various subsidiaries.
Premiers purpose is to explain how the whole is expected to be much greater than the sum of its parts. CEO Letcavage states, Our plan is to deliver a simple message that illustrates how the synergies between our three subsidiary companies, along with strategic alliances and partnerships, are creating a critical mass of transactions which can propel the company. With this message, we hope to clearly demonstrate why we were chosen Stock Pick of the Year by The Green Baron Report.
Premiers plan will begin with several microcap conferences including the SeeThruEquity conference in New York City early next year. The Company will schedule several additional speaking engagements, and is reviewing a number of investor awareness initiatives. Premier is coming off a successful recent appearance at a Financial Services Exchange (FSX) conference, and the Companys plans are to continue to deliver its attractive message to a wide audience.
Premier expects this campaign to dramatically raise investor and industry awareness, and demonstrate its inherent value and potential.
About Premier Holding Corporation
Under the corporate motto, "Everything Energy", Premier is an energy holding company focused on acquiring and integrating energy companies as synergistic subsidiaries. The Company accumulates residential and commercial clients in deregulated markets from all subsidiaries and cross sells energy and energy efficiency products and services, maximizing profit potential and minimizing cost of client procurement. In addition, Premier Holding provides top line management and financial support, which includes access to capital, financing, legal, insurance, mergers, acquisitions, joint ventures and management strategies. Additional integrated business offerings include direct energy services as power purchase agreements (PPAs), energy financing and leasing of generation programs in urban and rural real estate environments, lighting efficiency systems and refrigeration systems.
For more information visit PRHL Investors Relations www.prhlcorp.com.
IntelGenx (IGXT) to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
Saint Laurent, Quebec--(Newsfile Corp. - November 18, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time.
Institutional investors that wish to request a meeting with IntelGenx should contact the Cockrell Group on 877.889.1972877.889.1972.
A live broadcast of the conference presentation will be available. To access the broadcast, click here (http://wsw.com/webcast/sr4/igxt) or go to the Company's website at www.intelgenx.com. A replay of the conference presentation will also be available.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
IntelGenx (IGXT) Reports Q3, 2014 Results and Provides Corporate Development Update
Saint Laurent, Quebec--(Newsfile Corp. - November 12, 2014) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced financial results for the three and nine months ended September 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated.
Financial Results:
Cash on hand at September 30, 2014 decreased to $4.4 million and compares with a cash balance of $5.0 million as at December 31, 2013. The decrease in cash on hand at the end of Q3, 2014 relates to net cash used by operating activities of $1.6 million (2013: $0.7 million), net cash used in investing activities of $0.3 million (2013 - $0.3 million), and the negative effect of foreign exchange influences on cash balances of $0.3 million (2013: $Nil), partly offset by net cash provided by financing activities of $1.6 million (2013: $1.5 million).
Revenue of $0.8 million during the nine months ended September 30, 2014 (2013 - $0.8 million) includes $0.5 million (2013: 0.3 million) generated by Forfivo XL®, our first product approved by the U.S. Food and Drug Administration ("FDA"). Sales of Forfivo XL® experienced significant quarterly growth in 2014 to date. Net trade sales in the second quarter of 2014 grew by 55% when compared with the previous quarter, and grew by a further 31% in Q3, 2014. Net trade sales in the third quarter of 2014 were more than double those recorded in the first quarter. Management anticipates that sales of Forfivo XL® will continue to grow at a significant rate. Revenue for the nine months ended September 30, 2014 also includes an aggregate $0.3 million (2013: $0.5 million) in payments received for successfully achieving certain R&D development milestones for certain R&D development projects currently under development.
Total expenses in the first nine months of 2014 were $2.3 million compared with $1.8 million in the same period of 2013. The increase relates primarily to costs incurred in the development of our second Par project, which is progressing according to plan, and also to the costs of a pilot clinical study for our VersaFilm™ product for erectile dysfunction that was completed in Q1, 2014 and that indicated bioequivalence with the leading brand reference listed drug tadalafil product.
The net loss increased from $1.0 million in the first nine months of 2013 to $1.5 million in the same period of 2014 with the corresponding loss per share at $0.02 and $0.03 respectively.
Corporate Development Update
Equity Analyst Coverage by H.C. Wainwright
On July 1, 2014 we announced that H.C. Wainwright initiated equity analyst coverage of IntelGenx.
A copy of the initiation report can be accessed by clicking:
https://hcwco.bluematrix.com/docs/pdf/ff51024b-71e2-47c5-ab58-7d05118ab4aa.pdf.
All reports on us prepared by analysts represent the views of such analysts and are not necessarily those of IntelGenx. We are not responsible for the content, accuracy or timelines provided by analysts.
Anti-migraine VersaFilm™ product
On February 4, 2014, together with our co-development partner RedHill Biopharma Ltd. ("RedHill") (IntelGenx and RedHill together, the "Companies"), we announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the New Drug Application ("NDA") for our VersaFilm™ product for the treatment of acute migraines. The anti-migraine VersaFilm™ product is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. The questions raised by the FDA in the CRL regarding the NDA for the anti-migraine VersaFilm™ product primarily relate to Chemistry, Manufacturing and Controls ("CMC") and to the packaging and labeling of the product.
On March 3, 2014 the Companies announced the submission of a response to the FDA's CRL and on April 24, 2014 the Companies reported that the FDA had acknowledged receipt of our response and has requested additional CMC data, which the Companies believe they can supply based on available information. The Companies further reported that the supplier of the active pharmaceutical ingredient ("API") of the product is currently holding compliance discussions with the FDA following a temporary import ban of the API. These discussions are independent of RedHill and IntelGenx and are not specific to our anti-migraine VersaFilm™ product. The Companies are diligently working on a variety of options to ensure continued supply of the raw material regardless of the result of these compliance discussions and have already identified and audited an alternative active pharmaceutical ingredient ("API") supplier.
On April 28, 2014 the Companies announced the commencement of a comparative bioavailability clinical study comparing the anti-migraine VersaFilm™ product to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application and follows a positive scientific advice meeting with the German Federal Institute for Drugs and Medical Devices announced by RedHill in November 2013. On May 21, 2014 the Companies announced positive results from the comparative bioavailability study.
Subsequent to the end of the quarter, on October 1, 2014 the Companies announced that they have submitted a Marketing Authorization Application ("MAA") to the German Federal Institute for Drugs and Medical Devices ("BfArM") seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT®. The brand name RIZAPORT® was also conditionally approved by the FDA as part of the NDA review process in the U.S.
Government Funding for CNS VersaFilm™ product
On April 30, 2014 we announced financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support further development of a product for the treatment of central nervous system (CNS) diseases and disorders. The product will be based upon our proprietary, oral thin film, VersaFilm™, technology.
Subsequent to the end of the quarter, on November 3, 2014 we announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. The study data confirm that buccal absorption of the drug from the INT0036 film product results in a significantly higher bioavailability of the drug compared to oral tablets. Therapeutically relevant plasma concentrations are therefore reached significantly faster with the VersaFilm product compared to conventional tablets. We also announced that the product, INT0036, is indicated for the treatment of schizophrenia.
In order to maintain our competitive advantage, we are unable to disclose further details related to this project at this time.
Erectile Dysfunction VersaFilm™ product
On February 24, 2014 we announced the completion of a pilot biostudy with our proprietary VersaFilm™ tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug tadalafil product.
The successful outcome of this study enables us to finalize the optimization of the formulation and subsequently move on to pivotal activities.
U.S. patent allowances
On February 26, 2014 we announced receipt of a Notice of Allowance ("NOA") from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL®, our first FDA-approved product currently commercialized in the U.S.
On April 16, 2014 we announced receipt of a further NOA from the USPTO for U.S. Patent Application Serial No. 12/836,810 entitled "Oral mucoadhesive dosage form" which covers IntelGenx' proprietary AdVersa™ mucoadhesive drug delivery technology.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
iHookup Social, Inc. (OTC Pink: HKUP) Latest App Submission Receives Rapid Approval from Apple App Store
New App Displays Dynamic Monetization Engine
CAMPBELL, CA / ACCESSWIRE / November 12, 2014 / iHookup Social, Inc. (OTC Pink: HKUP), a mobile/social app that enables singles, groups and the socially active to connect quickly and efficiently, offering local, real life ‘hook-up’ opportunities, is pleased to announce that the Apple "App Store" has approved the company's most significant App Release to date and that it is now available for download in the Apple App Store.
As announced on November 10, 2014, the new App version provided a multitude of feature improvements, including improving connections with Facebook. The Company expects these latest advancements will enhance the user experience on many levels.
Notable among the myriad features in the newly approved iHookup Social app is the upgraded Facebook account creation process and entirely new Monetization Engine.
"Our entire team is over the top with excitement, to have delivered what we feel is the best iHookup Social App to date. Last month's decision to decrease our mobile advertising spends for the remainder of 2014 was directly related to bringing this new app live in November and I am very proud of our team for making it happen," stated Robert Rositano, Jr. CEO, iHookup Social. "Following our consistent efforts in testing price points and the conversion of a free user to a paid subscribers, updating our monetization touch points in this version is the next step in growing our average revenue per user (or ARPU) and ultimately growing revenues for the company through high volume user acquisition efforts," added Rositano.
iHookup has launched an Investor Portal and Information Center at http://www.glntv.tv/ihookup.
From time to time, iHookup Social will provide market updates, news and additional information via its website www.ihookupsocial.com, the Company's Facebook page and others www.facebook.com/ihookupnow.
iHookup Social, Inc.
iHookup Social, Inc. is a mobile Social Dating App positioned at the intersection of dating, social media and location-based connections.
About iHookup:
iHookup endeavors to enable singles, groups and the socially active to connect quickly and efficiently with local, real life 'hook-up' opportunities. This is the iHookup difference. Not only does the company's ever-refining technology help create meaningful connections of all varieties; it also facilitates the real-life meeting and offering-up of locally relevant locations to engage these new connections. These participating venues complete a circle of service that allows iHookup Social to be both matchmaker and concierge, providing a unique opportunity for consumer brands to offer incentives to a growing network of socially active singles and mobile users. iHookup Social, where real people make real connections... and where real businesses pay to be their host. www.ihookupsocial.com
Highbank (TSX VENTURE: HBK) -- Swamp Point North Site Update
VANCOUVER, BC--(Marketwired - November 06, 2014) - Highbank Resources Ltd. (the "Company") (TSX VENTURE: HBK).
President/CEO Victor Bryant reports.
Highbank's crew have moved the wash/screening plant and cone crusher to their final operational location adjacent to the Swamp Point North ("SPN") deposit. The task of moving the plant from sea level up 200 feet through three switchbacks was a difficult move. The wash plant and cone crusher (a +$400,000 piece of equipment) weighing approx. 80,000 lbs required careful handling. To ensure the safety of the crew and the equipment, Highbank barged in additional equipment for this move. A specialized semi-trailer tow truck was employed to act as a brake should the plant lose its purchase on the steep slope. Further specialized air bags were employed to alleviate any offsetting forces while an excavator traveled alongside ensuring no side forces deterred progress.
Over the course of the week a journeyman electrician will be powering up both the wash plant and the conveyor barge load-out facility. The power will come from two separate generators; one to supply the wash plant and the second for the barge loading conveyor facility.
Victor Bryant comments…"At this juncture I would like to apologize on behalf of myself, the management, contractors and employees for the delay in the SPN production timetable. Extreme weather conditions directly impacted our proposed plans, both in the removal of the overburden and the installation of key equipment. Of paramount importance in all our endeavours on the SPN project is the safety of all contractors, employees and equipment. The Company will not compromise these criteria now, or in the future."
It is anticipated that improved weather conditions forecast for November will assist in preparing the settling ponds for collection of the wash plant water sprays and enable the roads to be improved for hauling aggregate to the load-out hopper. Achievement of these objectives will regain some of the time lost as we progress towards our final goal.
Loan-Bonus Shares
Further to the TSX Venture Exchange acceptance for filing bulletin of October 27, 2014, the Company has issued a total of 227,273 bonus shares at a deemed price of $0.22 to various arm's length parties in consideration of loans advanced totaling $500,000. The shares are subject to a hold period from trading until February 28, 2015
Eternity Healthcare Inc. (ETAH), Sanofi Invests $11 Million Into Needle-Free Injection System
PHOENIX and VACOUVER, British Columbia, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Eternity Healthcare Inc. (ETAH), a medical device and diagnostic company with advanced technologies using the Needle-Free Injection system, announced today that its competitor company, Portal Instruments(R) Inc., has secured an $11 Million investment for their Needle-Free Injection System from Sanofi, this investment comes through their Sunrise initiative.
CAMBRIDGE, Mass. October 15, 2014 -- Portal Instruments, Inc., a new dynamic, emerging leader in the development of innovative drug delivery systems, announced today that it has completed a landmark $11 million Series A financing led by Sanofi through its Sunrise initiative along with PBJ Capital (a Boston-based venture firm) and a major US medical device company."
Dr. Salari, C.E.O. of Eternity Healthcare Inc. said: "With this new investment into the Needle-Free Injection Market, it shows that major pharmaceuticals and biotechnology companies are looking for alternative ways to administer their products, and appeal to the masses." He went on to state: "Using a Needle-Free Injection device can provide not only a pain free way to administer their products, but it is a more convenient way for patients to receive their medication." He concluded by saying: "Eternity Healthcare is one of the front runners in the Needle-Free Injection System Market and has on the market the Comfort-in(TM) Needle-Free Injection System. We currently have many products under development. These new products should capture the attention of other major pharmaceutical companies wishing to compete with Portal Instruments(R)."
Altima's (ARH.V) Completes Workover Operations at Chambers 3-17-41-11 W5M
November 4, 2014 / TNW-ACCESSWIRE / November 4 2014 / Altima Resources Ltd. (TSX-V: ARH / FSE: AKC / OTC Pink: ARSLF) announces that it has completed work-over operations on the UNE Chambers 3-17-41-11 W5M well.
Altima, through its joint venture with Acumen Energy Partners Inc. (refer to News Release August 6, 2014) completed work-over and flow-testing operations of the UNE Chambers 3-17-41-11 W5M well on October 30, 2014.
Rick Switzer, President and CEO of the Company reported that that existing packers and bridge plugs were recovered from the well bore and a total of six intervals were tested. Mr. Switzer commented: "After removing the packers and plugs to bottom, we were encouraged by the results from the first test intervals and made a decision to fracture stimulate an upper zone. The upper most formation was then isolated with a bridge plug set below the perforations and the interval was then fracture stimulated."
"Subsequent to the frac, much higher than anticipated bottom hole pressure was encountered. It was decided to leave the bridge plug in place and place the upper interval on production. At a later date when the bottom hole pressure has decreased, the Company will re-enter the well bore and remove the bridge plug to open up the bottom formations for commingled production. Although operations after the frac were very challenging, the Company is encouraged with the results."
Altima will now move forward in placing the well on production through the Conoco 9-4-41-11 W5M compressor station. Production is anticipated to commence within four to six weeks.
The Company's mostly contiguous land base at Chambers-Ferrier totals twenty-seven (27) sections (17,280 gross acres) with an approximate average working interest of 86% in 16 of the 27 sections and varying interests in eleven (11) wells.
IntelGenx (OTCQX:IGXT) Announces Successful Clinical Study for Schizophrenia
SAINT LAURENT, Quebec, Nov. 3, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company") today announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. INT0036 is indicated for the treatment of schizophrenia and utilizes the Company's proprietary VersaFilm™ technology.
The study data confirm that buccal absorption of the drug from the INT0036 film product results in a significantly higher bioavailability of the drug compared to oral tablets. Therapeutically relevant plasma concentrations are therefore reached significantly faster with the VersaFilm product compared to conventional tablets.
"The achievement of an improved pharmacokinetic profile, including reaching therapeutically relevant blood levels faster suggesting a potential faster onset of action, together with a shorter Tmax and a doubling of the bioavailability for the same loading, will provide patients suffering from schizophrenia with an attractive and much needed treatment alternative. The favourable pharmacokinetic profile is achieved via buccal absorption of the active pharmaceutical ingredient," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Our VersaFilm™ technology allows for an improved product that we believe will offer patients significant therapeutic benefits compared to existing medications. Our scientists are working diligently to progress the product to the next stage."
According to Datamonitor¹, sales of schizophrenia drugs across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) were estimated at $5.2 billion in 2012 and by 2021, the market is forecast to grow to $6.9 billion at a compound annual growth rate (CAGR) of 3.3%. The introduction of additional atypical antipsychotic depot injections, price increases in the US, and the use of pipeline drugs targeted against negative and cognitive symptoms alongside current antipsychotic treatments, are some of the catalysts for this growth. US sales were approximately $3.7 billion in 2012 and are forecast to grow at a CAGR of 4.7% until 2021.
As announced in April 2014, the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) is providing financial support for the development of this product.
In order to maintain our competitive advantage, we are unable to disclose further details related to this project at this time.
¹Datamonitor Healthcare schizophrenia forecast published July 13, 2012
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com
iHookup Social (HKUP) Reaches Top 10 in Apple App Store Paid Apps
CAMPBELL, CA, United States, via ETELIGIS INC., 10/30/2014 - - iHookup Social, Inc. (OTC Pink: HKUP) (PINKSHEETS: HKUP), a mobile/social app that enables singles, groups and the socially active to connect quickly and efficiently, offering local, real life hook-up opportunities, is pleased to announce that the Companys app has reached #9 on the highly competitive Paid App category for Social Networking in the United States. The ascension in the rankings is the iHookup Socials highest to date and places it well above some of the preeminent brands in the mobile social dating marketplace.
We are very pleased to see the App rise to a top 10 ranking among paid apps in our category, stated Robert Rositano, CEO, iHookup Social. This rise in ranking through a period of strategy adjustment for the company is most notable and can be attributed to the companys focus on organic growth and virility of the mobile-social dating category, along with our ongoing test media, a reduced advertising spend and our further refinement of our in-app pricing model.
Macintosh HD:Users:dean:Desktop:PR_Final.png
The Company has also announced that beginning October and for the remainder of Q4 2014, the Company has shifted a portion of its resources from acquisition of downloads to bolstering SEO, adding social marketing efforts, adding venue based offers as well as testing additional channels of public relations outreach. The Companys mobile media partner and strategic advisor, Deep Forest Media, has strongly encouraged the Company to focus on community development and engagement, versus paying the greatly increased advertising rates for app marketing in the final three months of the year. App marketing prices rise sharply in Q4, driven by major retailers and holiday ad buys by the industry top brands.
While this strategic diversion of Company resources may reduce our download and registered user growth during the period, it also allows us to enhance features and target locally recognized events to engage our current community of iHookup Social users, stated Rositano. Our recent inclusion on Facebooks App Center is one venue which we firmly believe requires additional attention and resources. Avoiding an over spend during the holidays affords us an opportunity to take advantage of the tremendous Facebook opportunity and to prepare for a focused effort moving toward Valentines Day and the first quarter.
iHookup has launched an Investor Portal and Information Center at http://www.glntv.tv/ihookup.
From time to time, iHookup Social will provide market updates, news and additional information via its website www.ihookupsocial.com, the Company's Facebook page and others www.facebook.com/ihookupnow .
iHookup Social, Inc.
iHookup Social, Inc. is a mobile Social Dating App positioned at the intersection of dating, social media and location-based connections.
Levon Resources Ltd.(TSX:LVN) Announces a USD $1 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 24, 2014) - Levon Resources Ltd. (the Company) (TSX:LVN)(OTCQX:LVNVF)(BERLIN: LO9)(FRANKFURT:LO9) is pleased to announce it is undertaking a USD $1 million private placement (the "Placement").
A total of 4,400,000 common shares of Levon will be issued in the Placement at a price of CAD $0.25 per share. To Levon's knowledge, no new insiders of Levon will be created as a result of the Placement. Completion of the Placement is subject to the approval of the Toronto Stock Exchange.
The common shares to be sold in the Placement have not been registered under the United States Securities Act of 1933, as amended, or any applicable state securities laws and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the foregoing securities in any jurisdiction, including in the United States, in which such offer, solicitation or sale would be unlawful.
About Levon Resources Ltd.
Levon is a gold and precious metals exploration Company, exploring the company's 100% owned flagship Cordero bulk tonnage silver, gold, zinc, and lead project near Hidalgo Del Parral, Chihuahua, Mexico.
ON BEHALF OF THE BOARD
Ron Tremblay, President and Chief Executive Officer
Highbank (TSX VENTURE: HBK) Applauds B.C. Government's Reduced LNG Levy
VANCOUVER, BC--(Marketwired - October 24, 2014) - Highbank Resources Ltd. (the "Company") (TSX VENTURE: HBK) (FRANKFURT: V7O).
President/CEO Victor Bryant comments… "The Highbank board of directors whole-heartedly applaud B.C. Premier Christy Clark and her Ministers on their revised B.C. LNG export levy." This revised tax structure should most assuredly entice the energy behemoths (1) of the recently formed B.C. LNG Developers Alliance, comprising Malaysian state controlled Petronas-led Pacific Northwest LNG; Shell Canada Energy-led LNG Canada; BG Group PLC's Prince Rupert LNG; and the Kitimat LNG project, which is co-owned with the Canadian units of Chevron.
Commenting to Bloomberg, one of the Alliance members (Royal Dutch Shell) stated, "We are pleased to have certainty on a final B.C. LNG tax framework". David Keane, President of the BC LNG Alliance added, "We appreciate the fact that the government has revisited their original tax."
LNG Canada, the Kitimat-based LNG project led by Shell, issued a further statement that appears supportive of the government tax structure unveiled Tuesday. "We are of the view that the BC LNG tax framework announced by the government provides balance and consideration of the global challenges in the LNG marketplace faced by the LNG sector in B.C.," the company said in a statement. "We consider it an important input to our decision-making process."
This LNG levy regime will be of tremendous benefit to Highbank, which is poised to commence production at its NI 43-101 compliant, aggregate deposit on the Portland Canal. To put the scope of the proposed development of LNG in B.C. in perspective the following map indicates the location to the companies' involved. (2)
Currently high rainfall at the site is delaying gravel preparation. However, the delay is allowing work to proceed on winterizing the camp, completing a dry storage area for equipment and supplies, and other infrastructure work around the barge load-out site.
(1) urlm.in/tbdk
(2) http://ow.ly/Dc08t
Shares for Debt
Further to the TSX Venture Exchange acceptance for filing bulletin of October 15, 2014, the Company has issued a second tranche of 1,193,000 shares at a deemed price of $0.22 to settle a debt of $262,500 to Foresight Innovations Ltd. of Victoria, B.C. The shares are subject to a hold period from trading until February 17, 2015.
On behalf of the Board of Directors of HIGHBANK RESOURCES LTD.
"Victor N. Bryant"
Victor N. Bryant, CEO/President